# Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT 3 and 5-HT 6 Receptor Antagonist with Antipsychotic and Procognitive Properties

Pawel Zajdel, Katarzyna Grychowska, Szczepan Mogilski, Rafal Kurczab, Grzegorz Satala, Ryszard Bugno, Tomasz Kos, Joanna Golębiowska, Natalia Malikowska-Racia, Agnieszka Nikiforuk, et al.

► To cite this version:

Pawel Zajdel, Katarzyna Grychowska, Szczepan Mogilski, Rafal Kurczab, Grzegorz Satala, et al. Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT 3 and 5-HT 6 Receptor Antagonist with Antipsychotic and Procognitive Properties. Journal of Medicinal Chemistry, 2021, 64 (18), pp.13279-13298. 10.1021/acs.jmedchem.1c00224. hal-03357806

HAL Id: hal-03357806

https://hal.science/hal-03357806

Submitted on 16 Oct 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT₃ and 5-HT₆ Receptor Antagonist with Antipsychotic and Procognitive Properties

Paweł Zajdel,* Katarzyna Grychowska, Szczepan Mogilski, Rafał Kurczab, Grzegorz Satała, Ryszard Bugno, Tomasz Kos, Joanna Gołębiowska, Natalia Malikowska-Racia, Agnieszka Nikiforuk, Séverine Chaumont-Dubel, Xavier Bantreil, Maciej Pawłowski, Jean Martinez, Gilles Subra, Frédéric Lamaty, Philippe Marin, Andrzej J. Bojarski, and Piotr Popik*

<figure><img src="image_2.png" /></figure>

Cite This: J. Med. Chem. 2021, 64, 13279–13298

<figure><img src="image_3.png" /></figure>

Read Online

## ACCESS

<figure><img src="image_4.png" /></figure>

Metrics & More

<figure><img src="image_5.png" /></figure>

Article Recommendations

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>

Supporting Information

<figure><img src="image_8.png" /></figure>

**ABSTRACT:** In line with recent clinical trials demonstrating that ondansetron, a 5-HT₃ receptor (5-HT₃R) antagonist, ameliorates cognitive deficits of schizophrenia and the known procognitive effects of 5-HT₆ receptor (5-HT₆R) antagonists, we applied the hybridization strategy to design dual-acting 5-HT₃/5-HT₆R antagonists. We identified the first-in-class compound FPPQ, which behaves as a 5-HT₃R antagonist and a neutral antagonist 5-HT₆R of the Gs pathway. FPPQ shows selectivity over 87 targets and decent brain penetration. Likewise, FPPQ inhibits phencyclidine (PCP)-induced hyperactivity and displays procognitive properties in the novel object recognition task. In contrast to FPPQ, neither 5-HT₆R inverse agonist SB399885 nor neutral 5-HT₆R antagonist CPPQ reversed (PCP)-induced hyperactivity. Thus, combination of 5-HT₃R antagonism and 5-HT₆R antagonism, exemplified by FPPQ, contributes to alleviating the positive-like symptoms. Present findings reveal critical structural features useful in a rational polypharmacological approach to target 5-HT₃/5-HT₆ receptors and encourage further studies on dual-acting 5-HT₃/5-HT₆R antagonists for the treatment of psychiatric disorders.

<figure><img src="image_9.png" /></figure>

## INTRODUCTION

Schizophrenia is a debilitating mental disorder characterized by the presence of positive (hallucinations, delusions) and negative (social withdrawal, flat affect, low motivation) symptoms that are usually accompanied by cognitive impairment (e.g., learning and attention deficits). Despite the steady stream of antipsychotic drugs acting at a variety of monoamine receptors, the clinical management of schizophrenia is far from optimal. A significant number of patients under antipsychotic treatment experience persistent symptoms and an impaired quality of life. Approximately 30% of patients diagnosed with schizophrenia do not respond or only partially respond to existing drugs,¹ with inadequate control of the core positive symptoms and relative inefficacy in treating the negative and cognitive symptoms.

A detailed analysis of the receptor profile of clozapine, the only antipsychotic used in treatment-resistant schizophrenia,²,³ in addition to well-known blockade of serotonin type 2A (5-HT₂A) receptor, revealed the antagonistic properties at the serotonin type 3 receptor (5-HT₃R)⁴ and serotonin type 6 receptor (5-HT₆R).⁵ Although concurrent blockade of the muscarinic, histamine, and dopamine receptors hampers procognitive properties of clozapine,¹,⁶ its high affinity for

<figure><img src="image_10.png" /></figure>

<figure><img src="image_11.png" /></figure>
both 5-HT<sub>3</sub>R and 5-HT<sub>6</sub>R has triggered academic and industrial research.

Among the 14 serotonin receptor subtypes,⁷ 5-HT<sub>3R</sub> is a unique ionotropic receptor that belongs to the pentameric ligand-gated ion channel (LGIC) superfamily. 5-HT<sub>3R</sub> is located in both the CNS and periphery (including the small intestine and colon). Presynaptic 5-HT<sub>3Rs</sub> regulate calcium influx into nerve terminals, thus modulating the release of neurotransmitters in different brain areas (hippocampus, putamen, caudate nucleus, amygdala), while postsynaptic receptors located on GABA interneurons are associated with fast excitatory sodium and potassium depolarization.<sup>8–10</sup> Blockade of presynaptic 5-HT<sub>3R</sub> inhibits overactive meso-limbic dopamine activity and GABA release and increases acetylcholine neurotransmission in the hippocampus and cortex. At the same time, blockade of 5-HT<sub>3R</sub> located in GABAergic interneurons enhances glutamatergic transmission. Ondansetron and granisetron, which behave as 5-HT<sub>3R</sub> antagonists, failed to alleviate the positive symptoms of psychosis. Still, they reduced the negative symptoms and improved cognitive symptoms when administered as adjuvant therapy to antipsychotics.<sup>11–13</sup> Finally, 5-HT<sub>3R</sub> antagonists reduce haloperidol- and 5-hydroxytryptophan-induced extrapyramidal side effects, i.e., catalepsy and tardive dyskinesia.<sup>12,14,15</sup>

5-HT<sub>6R</sub> is a Gs-coupled receptor (GPCR) that is almost exclusively expressed in the CNS and is abundant in brain regions involved in cognitive functions such as the prefrontal cortex, hippocampus, and striatum. It is located postsynaptically to serotonergic neurons and is primarily localized in the primary cilium, a sensory organelle that participates in neurodevelopmental processes.

Recent studies on the 5-HT<sub>6R</sub> interactome identified additional signaling pathways, including the Fyn tyrosine kinase,<sup>16</sup> mechanistic target of rapamycin (mTOR, involved in synaptic plasticity and cognition),<sup>17</sup> and cyclin-dependent kinase 5 (Cdk5) pathway,<sup>18</sup> which is critical for neuron migration and neurite growth. 5-HT<sub>6R</sub> antagonists improve cognitive performance in a wide range of preclinical models of cognitive impairment.<sup>19–21</sup> The beneficial effects of 5-HT<sub>6R</sub> antagonists on cognition have been attributed to the enhanced release of acetylcholine and glutamate in the frontal cortex and hippocampus.<sup>22,23</sup> Finally, the selective 5-HT<sub>6R</sub> antagonists—idalopirdine and AVN-211—have advanced to phase II and phase IIa clinical trials, respectively, as add-on therapies against schizophrenia, but the results were not conclusive.<sup>24,25</sup>

Given their role in different paradigms of cognitive impairment, 5-HT<sub>3R</sub> and 5-HT<sub>6R</sub> are promising targets for the development of dual-acting compounds with presumably more efficient therapeutic effects than selective agents (Figure 1).<sup>26,27</sup> The molecular framework for developing compounds that target both receptors arises from the structural similarity of pyrroloquinoxaline I, a 5-HT<sub>3R</sub> ligand,<sup>28</sup> and CPPQ, a pyrroloquinoline-based 5-HT<sub>6R</sub> antagonist (Figure 2).<sup>29</sup> The rationale toward “selective unselective” compounds was achieved using a hybridization strategy, which involved merging the pharmacophores of I and CPPQ into a unique molecular entity.<sup>30–32</sup>

Based on a combination of rational design and *in silico* analysis, we evaluated the structure-activity relationships of dual-acting 5-HT<sub>3</sub>/5-HT<sub>6</sub>R antagonists. Structural modifications comprised diversification of the amine fragment at position 4 of the 1H-pyrrolo[3,2-c]quinoline core and

<figure><img src="image_12.png" /><figcaption>**Figure 1.** Schematic representation of the hypothetical influence of dual 5-HT<sub>3</sub>/5-HT<sub>6</sub>Rs antagonists on mTOR activity and neurotransmitters release.</figcaption></figure>

functionalization of the *N*¹ atom of the tricyclic scaffold with various arylsulfonyl moieties. We selected a lead compound 1-[(3-fluorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline (FPPQ) with balanced target activity (leaving 87 targets unaffected) and favorable oral absorption and CNS penetration. Similar to the reference drug clozapine, FPPQ attenuated phencyclidine (PCP)-induced hyperlocomotion, and enhanced novelty discrimination of PCP-treated rats in the novel object recognition (NOR) test. These data might support the potential antipsychotic activity of FPPQ that relies on its dual 5-HT<sub>3</sub>/5-HT<sub>6</sub>R antagonism.

## RESULTS AND DISCUSSION

**Synthesis.** Designed compounds 6–28 were synthesized in a multistep synthetic pathway starting from pyrroline 1 obtained according to our previously reported method (Scheme 1).<sup>33,34</sup> Subsequent aromatization to pyrrole derivative 2, followed with reduction of nitro group, then cyclization of arylpyrrole derivative to lactam 3, and chlorination of the latter afforded 1H-pyrrolo[3,2-c]quinoline 4. Stirring of key synthon 4 with the respective primary amines required prolonged heating in acetonitrile under microwave-assisted conditions to yield amino derivatives 5a and 5b. On the other hand, the reaction with secondary amines proceeded smoothly in the presence of triethylamine (TEA) in refluxing toluene to furnish amino derivatives 5c–5f. Subsequent coupling with selected sulfonyl chlorides in the presence of phosphazene base P1-t-Bu-tris(tetramethylene) (BTPP) provided sulfonamide derivatives 6–28.<sup>35</sup> The Boc-protected products were finally converted into the HCl salts of secondary amines upon treatment with 1 M HCl solution in methanol.

**Structure–Activity Relationship Studies.** To initiate the quest for dual-acting 5-HT<sub>3</sub>/5-HT<sub>6R</sub> antagonists, the approach entailed identification of the common structural features of known 5-HT<sub>3R</sub> and 5-HT<sub>6R</sub> ligands (Figure 2). Molecular docking analysis indicated that pyrroloquinoxaline I, a 5-HT<sub>3R</sub> ligand, shows coherent binding mode with that of granisetron – a 5-HT<sub>3R</sub> antagonist (Figure 3A).<sup>36</sup> Further analysis of pyrroloquinoxaline I, suggested that pyrroloquinoline 5d, with the bridgehead nitrogen shifted to position 1 of the pyrrole ring, would occupy the same binding site in 5-HT<sub>3R</sub>. The pyrroloquinoline moiety is constrained by the CH–π interaction with W63, and cation–π interaction with R65 in the 5-HT<sub>3R</sub> binding site, whereas the positively charged methyl piperazine moiety is located in the pocket formed by W156, Y207, F199, W63, and E209. Mutual spatial relationships enable the creation of cation–π interactions, trapping the charged methyl piperazine fragment between the side chains of W156 on one side and F199/Y207 on the other side (Figure 3A).
<figure><img src="image_13.png" /><figcaption>Figure 2. Strategy for the design of dual-acting 5-HT<sub>3</sub>/5-HT<sub>6</sub>Rs antagonists.</figcaption></figure>

**Scheme 1.** Synthetic Pathway Leading to Compounds 6–28: (i) Na-OtBu, DMF, rt, 2 h; (ii) H<sub>2</sub>, Pd/C, MeOH, rt, 2 h; (iii) AcOH, sec-BuOH, 60°C, 3 h; (iv) POCl<sub>3</sub>, 105°C, 4 h; (v) primary amine, MeCN, MW 140°C, 7 h or secondary amine, TEA, toluene, 114 °C, o/n; (vi) arylsulfonyl chloride, BTPP, CH<sub>2</sub>Cl<sub>2</sub>, 0°C → rt, 3 h; (vii) 1M HCl/MeOH, rt, 5 h

<figure><img src="image_14.png" /></figure>

As revealed by the functional ex vivo assays, which measured the effects of the compounds on guinea pig ileum contractions induced by serotonin (5-HT), pyrroloquinoline 5d similarly to 5-HT induced contraction of ileum and was classified as an agonist at 5-HT<sub>3</sub>R (100% response of serotonin used as control agonist at 100 nM) (Table 1). Its demethylated analogue 5e behaved as a partial agonist in this assay (43% response at 300 nM).

Closer inspection of the binding mode of 5d in 5-HT<sub>3</sub>R showed that the binding pocket filled with the tricyclic scaffold leaves some space for structural modifications. Extension of the pyrroloquinoline core at the N<sup>1</sup> atom with a phenylsulfonyl fragment enabled a distinct cation-π interaction with R169, which stabilized the ligand-receptor (L-R) complex (Figure 3C). Of note, compounds 6 and 7, bearing phenylsulfonyl fragment, did not exert any contractile effect on the guinea pig ileum, but efficiently inhibited serotonin-induced contraction of the tissue. Thus, the introduction of a phenylsulfonyl fragment switched the initial agonist activity at 5-HT<sub>3</sub>R (5d,

5e) into antagonistic properties (6, 7), leading the functional properties in the desired direction (Table 1).

Introducing a hydrophobic fragment, linked via a double electron-acceptor sulfonyl group to the pyrroloquinoline core, was also advantageous for interaction with 5-HT<sub>6</sub>R. This modification allowed us to construct the framework required for 5-HT<sub>6</sub>R antagonism, as revealed by the inhibitory activity of arylsulfonyl derivatives 6 and 7 in the cAMP assay performed in 1321N1 cells (Table 1). A similar trend was observed for the 5-HT<sub>6</sub>R binding data (6 K<sub>i</sub> = 2 nM vs 5d K<sub>i</sub> = 245 nM; 7 K<sub>i</sub> = 11 nM vs 5e K<sub>i</sub> = 757 nM, Table 1). The docking analysis results showed that the introduction of phenylsulfonyl fragment (6) did not significantly change the binding mode compared with the reference analogue 5d (Figure 3B,D). Nevertheless, the phenylsulfonyl fragment interacts with the hydrophobic pocket formed by helixes 3–5 in 5-HT<sub>6</sub>R and additionally stabilizes L-R complex.

Next, we focused on the planar pyrroloquinoline skeleton's role in the interactions with 5-HT<sub>3</sub>R and 5-HT<sub>6</sub>R. Consistent with the binding model, the fused benzene ring in the pyrroloquinoline core forms an additional cation-π interaction with R65 (Figure 4). Its deletion, which resulted in the degradation of the pyrroloquinoline to the azaindole core, was detrimental for targeting the 5-HT<sub>3</sub> site (II vs 7). This observation is in line with data reported for pyrroloquinoxaline and imidazoquinoxaline series, where removal of the fused benzene ring led to a loss of antagonistic activity at 5-HT<sub>3</sub>R.<sup>38</sup>

Further considerations, employing combined medicinal chemistry and docking approaches, functionalized the C<sup>4</sup> position of the pyrroloquinoline core with various alicyclic amines (Table 2, Supporting Information Table S1). Based on the geometry of the interactions between the protonated basic group and R65/Y207 for 5-HT<sub>3</sub>R (cation-π) (Figure 3E), and D3.32 (salt bridge) for 5-HT<sub>6</sub>R (Figure 3F), the designed structures were scored and subsequently selected for synthesis (Table 2).

Replacement of the 3-aminopyrrolidine fragment present in CPPQ with 3-aminoazetidine, connected to a pyrroloquinoline moiety by the exocyclic nitrogen atom, did not significantly influence the antagonist properties for 5-HT<sub>3</sub>R (9 vs 8). In contrast, introduction of secondary amines, connected to the pyrroloquinoline core by endocyclic nitrogen, was beneficial in terms of antagonist potency for this target (6, 7, 10, 11 vs 8) (Tables 1 and 2).

In turn, the antagonist properties at 5-HT<sub>6</sub>R were strongly affected by the alicyclic ring's size, since four- and seven-membered rings reduced antagonist activity at this site. These
<figure><img src="image_15.png" /><figcaption>**Figure 3.** Illustration of binding modes of selected compounds in the orthosteric binding site of 5-HT₃R (PDB ID: 6NP0) and 5-HT₆R (a homology model built on a β2 adrenergic template; PDB ID: 4LDE). Comparison of binding modes of compound I (cyan), 5d (green) vs granisetron (orange) in 5-HT₃R (A), and I vs 5d in 5-HT₆R (B). (C, D) Binding modes of 5d (green) and 6 (yellow) in 5-HT₃R and 5-HT₆R, respectively. (E, F) Illustration of the binding modes for analogues with five-membered (8; violet) and six-membered (17; magenta) aliphatic ring containing nitrogen atom in 5-HT₃ and 5-HT₆Rs, respectively.</figcaption></figure>

observations indicate that only the six-membered piperazine ring in the C⁴ position of the pyrroloquinoline core ensures the desired pharmacological profile at both targets (Table 2, Figure 3E,F).

We next explored the optimal substituents in the arylsulfonyl part (Table 3). Among the methyl piperazine derivatives (12–14), no substantial difference in antagonist potency at 5-HT₆R was observed between compounds bearing halogen atoms in position 3 and their unsubstituted congener (12, 13 vs 6). On the other hand, an introduction of a fluorine atom in position 3 of the arylsulfonyl moiety was highly favorable in terms of antagonist properties at 5-HT₃R (12, 74% at 100 nM vs 6, 28% at 100 nM).

Because metabolic stability experiments using rat liver microsomes revealed higher susceptibility of N-methylated derivatives to metabolic enzymes (12, Clᵢₘt = 32.65 µL/min/mg vs 17, Clᵢₘt = 12.8 µL/min/mg; 6, Clᵢₘt = 38.57 µL/min/mg vs 7, Clᵢₘt = 4.48 µL/min/mg), only unsubstituted derivatives were submitted for further investigation.

Among the desmethyl analogues, the introduction of a fluorine atom in position 3 improved antagonist activity at 5-HT₃R (17, pD₂' = 7.43) and increased the antagonist properties for 5-HT₆R (Kₐ = 2 nM) up to 5-fold compared with the unsubstituted compound 7 (Tables 1 and 3). Regardless of the substituents' electronic properties, the presence of chlorine atom, methyl or methoxy group did not significantly affect antagonist activity at either receptor (18, 20, 21 vs 7).

Shifting of the halogen atom from position 3 to 2 of the arylsulfonyl fragment slightly decreased antagonist properties at 5-HT₆R (18 vs 16). Substitution at position 4 (22–24) afforded a drop in antagonist effects at both targets, regardless of the substituent's volume and electronic properties.

3,4-Difluoro and 3,4-dichloro derivatives (25, 26 vs 18) revealed an unfavorable effect of the 3,4-disubstitution pattern on the antagonist properties at the 5-HT₆R. On the other hand, the introduction of fluorine atoms at positions 2 and 5 (27) maintained activity at 5-HT₆R but decreased antagonist potency at the 5-HT₃ sites. Subsequently, expansion of the aromatic ring system by introduction of a naphthyl moiety reduced antagonist potency at 5-HT₆R (28).

In summary, in the desmethylpiperazine series, monosubstitution of the arylsulfonyl fragment with halogen atoms (17, 18) or small electron-donating substituents (20) in position 3, was the most favorable modifications to ensure antagonist properties at both targets.

Based on its highest antagonistic potency at both 5-HT₃R and 5-HT₆R (pD₂' (5-HT₃R) = 7.43, Kₐ (5-HT₆R) = 2 nM, Table 3) and metabolic stability (Clᵢₘt = 12.8 µL/min/mg), FPPQ was selected for a more detailed evaluation. Additionally, compounds 18 and 20 were chosen for in vitro evaluation for their selectivity over selected GPCRs (Table 4). These experiments confirmed a class-effect selectivity over 5-HT₁A, 5-HT₂A, and 5-HT₇ receptors. Importantly, evaluated derivatives did not bind to dopaminergic D₂Rs. Therefore, these compounds might be devoid of the side effects associated
<figure><img src="image_16.png" /><figcaption>Table 1. Agonist/Antagonist Properties of Compounds 5d, 5e, 6, 7, II, and Ondansetron for 5-HT₃Rs, and Antagonist Properties and Binding Data of Compounds 5d, 5e, 6, 7, II, Ondansetron, Intepirdine, and SB399885 for 5-HT₆Rs</figcaption></figure>

<table><thead><tr><th rowspan="2">compound</th><th rowspan="2">core</th><th rowspan="2">R</th><th colspan="3">5-HT<sub>3</sub>R</th><th colspan="2">5-HT<sub>6</sub>R</th></tr><tr><th>agonist effect<sup>b</sup></th><th>antagonist effect<sup>c</sup></th><th>pD<sub>2</sub><sup>d</sup></th><th>K<sub>b</sub> [nM]<sup>e</sup></th><th>K<sub>i</sub> [nM]<sup>f</sup></th></tr></thead><tbody><tr><td>5d</td><td>A</td><td>CH<sub>3</sub></td><td>100 (100 nM)</td><td>NT</td><td>NT</td><td>&gt;10 000</td><td>245</td></tr><tr><td>5e</td><td>A</td><td>H</td><td>9 (100 nM) 43 (300 nM)</td><td>NT</td><td>NT</td><td>&gt;10 000</td><td>757</td></tr><tr><td>6</td><td>B</td><td>CH<sub>3</sub></td><td>NT</td><td>28 (100 nM) 48 (300 nM)</td><td>NT</td><td>4</td><td>2</td></tr><tr><td>7</td><td>B</td><td>H</td><td>NT</td><td>26 (100 nM) 60 (300 nM)</td><td>6.43</td><td>17</td><td>11</td></tr><tr><td>II<sup>a</sup></td><td></td><td></td><td>NT</td><td>7 (300 nM)</td><td>NT</td><td>1</td><td>6</td></tr><tr><td>ondansetron</td><td></td><td></td><td>NT</td><td>pA<sub>2</sub> = 7.11 ± 0.12</td><td>NT</td><td>&gt;10 000</td><td>NT</td></tr><tr><td>intepirdine</td><td></td><td></td><td>NT</td><td>NT</td><td>NT</td><td>1.2</td><td>1.4</td></tr><tr><td>SB399885</td><td></td><td></td><td>NT</td><td>NT</td><td>NT</td><td>1.6</td><td>0.7</td></tr></tbody></table>

<sup>a</sup>Compound reported in ref 37. For synthesis, see Supporting Information Scheme S1. <sup>b</sup>The effect induced by the tested compounds at the concentration of 100 or 300 nM expressed as a percent of maximal contraction of guinea pig ileum induced by control agonist (5-HT). <sup>c</sup>Percent inhibition of response to stimulation by 5-HT (contraction of guinea pig ileum) at the concentration of 3 µM induced by different concentrations of tested compounds shown in brackets (N = 6–8, SEM ≤ 12%). <sup>d</sup>Antagonist potency expressed as pD<sub>2</sub>' (N = 6–8, SEM ≤ 14%). <sup>e</sup>Mean K<sub>b</sub> values based on two independent experiments in 1321N1 cells (SEM ≤ 22%). <sup>f</sup>Mean K<sub>i</sub> values based on three independent binding experiments in HEK cells stably expressing h5-HT<sub>6</sub>R (SEM ≤ 15%).

<figure><img src="image_17.png" /><figcaption>Figure 4. Binding modes of compounds 7 (brown), II (lemon), and granisetron (orange) in the active site of 5-HT<sub>3</sub> (PDB ID: 6NP0).</figcaption></figure>

with D<sub>2</sub>R blockade, such as extrapyramidal symptoms and prolactin release.

In addition to ex vivo functional evaluation of the series of pyrroloquinolines at 5-HT<sub>3</sub>R in guinea pig ileum, FPPQ was profiled in the electrophysiological method using h5-HT<sub>3</sub>R ion channel cell-based antagonist IonFlux assay. In this cellular model, FPPQ inhibited inward currents in response to the 5-HT addition, and behaved as an antagonist (IC<sub>50</sub> = 0.0676 µM). A similar effect at h5-HT<sub>3</sub>R was observed for palonosetron (IC<sub>50</sub> = 0.0017 µM) used as a reference 5-HT<sub>3</sub>R antagonist.

To further assess the selectivity of FPPQ, SafetyScreen profiling was conducted at Eurofins (Table 5, Supporting Information Table S2). This experimental panel of 87 receptors, ion channels, transporters, and enzymes assesses interactions with proteins that are distinct from the intended molecular target and predicts potential clinical adverse effects. FPPQ displayed > 1–3 orders of magnitude higher affinity for

<figure><img src="image_18.png" /><figcaption>Table 2. Antagonist Properties of Compounds 8–11 at 5-HT<sub>3</sub> and 5-HT<sub>6</sub> Receptors<sup>a,b</sup></figcaption></figure>

<table><thead><tr><th rowspan="2">Compound</th><th rowspan="2">R</th><th colspan="2">Antagonist effect</th></tr><tr><th>5-HT<sub>3</sub>R<sup>a</sup></th><th>5-HT<sub>6</sub>R<sup>b</sup></th></tr></thead><tbody><tr><td>8</td><td><img src="image_8.png" alt="Chemical structure of 5-HT<sub>3</sub>R agonist"></td><td>32</td><td>93</td></tr><tr><td>9</td><td><img src="image_9.png" alt="Chemical structure of 5-HT<sub>3</sub>R antagonist"></td><td>35</td><td>15</td></tr><tr><td>10</td><td><img src="image_10.png" alt="Chemical structure of 5-HT<sub>3</sub>R antagonist"></td><td>48</td><td>78</td></tr><tr><td>11</td><td><img src="image_11.png" alt="Chemical structure of 5-HT<sub>3</sub>R antagonist"></td><td>53</td><td>41</td></tr></tbody></table>

<sup>a</sup>Percent inhibition of response to stimulation by 5-HT (contraction of guinea pig ileum) at the concentration of 3 µM induced by tested compounds (300 nM). <sup>b</sup>Percent inhibition of control agonist response at 10<sup>-6</sup> M; performed in duplicate in 1321N1 cells.

5-HT<sub>3</sub>R and 5-HT<sub>6</sub>R than for an array of receptors and enzymes expressed in the brain. Cardiac safety assessment of FPPQ was based on its lack of agonistic effect at 5-HT<sub>2B</sub>R (3.6% inhibition at 1 µM) which is indicative of valvulopathy and reasonably high selectivity (1000-fold) over hERG
<figure><img src="image_19.png" /><figcaption>Table 3. Antagonist Properties and Binding Data of Compounds 12–28, Ondansetron, and Intepirdine at 5-HT<sub>3</sub> and 5-HT<sub>6</sub> Receptors Suggest That Dual-Acting 5-HT<sub>3</sub>/5-HT<sub>6</sub>R Antagonists (17, 18, 20) Display the Most Favorable Profile</figcaption></figure>

<table><thead><tr><th rowspan="2">compound</th><th rowspan="2">Ar</th><th rowspan="2">R</th><th colspan="2">5-HT<sub>3</sub>R</th><th colspan="3">5-HT<sub>6</sub>R</th></tr><tr><th>antagonist effect<sup>a</sup></th><th>pD<sub>2</sub><sup>b</sup></th><th>antagonist effect<sup>c</sup></th><th>K<sub>b</sub> [nM]<sup>d</sup></th><th>K<sub>i</sub> [nM]<sup>e</sup></th></tr></thead><tbody><tr><td>12</td><td>3-F-Ph</td><td>CH<sub>3</sub></td><td>30 (30 nM) 74 (100 nM)</td><td>7.33</td><td>83</td><td>6</td><td>2</td></tr><tr><td>13</td><td>3-Cl-Ph</td><td>CH<sub>3</sub></td><td>10 (100 nM) 44 (300 nM)</td><td>NT</td><td>90</td><td>5</td><td>2</td></tr><tr><td>14</td><td>4-F-Ph</td><td>CH<sub>3</sub></td><td>NT</td><td>NT</td><td>75</td><td>7</td><td>10</td></tr><tr><td>15</td><td>2-Br-Ph</td><td>H</td><td>NT</td><td>NT</td><td>69</td><td>NT</td><td>13</td></tr><tr><td>16</td><td>2-Cl-Ph</td><td>H</td><td>NT</td><td>NT</td><td>75</td><td>50</td><td>5</td></tr><tr><td>17 FPPQ</td><td>3-F-Ph</td><td>H</td><td>32 (100 nM) 78 (300 nM)</td><td>7.43</td><td>92</td><td>2</td><td>3</td></tr><tr><td>18</td><td>3-Cl-Ph</td><td>H</td><td>11 (100 nM) 72</td><td>6.71</td><td>100</td><td>32</td><td>3</td></tr><tr><td>19</td><td>3-CF<sub>3</sub>-Ph</td><td>H</td><td>21 (100 nM) 37 (300 nM)</td><td>6.09</td><td>82</td><td>17</td><td>3</td></tr><tr><td>20</td><td>3-Me-Ph</td><td>H</td><td>20 (30 nM) 40 (100 nM)</td><td>6.74</td><td>89</td><td>38</td><td>3</td></tr><tr><td>21</td><td>3-OMe-Ph</td><td>H</td><td>28 (100 nM) 73 (300 nM)</td><td>6.38</td><td>82</td><td>32</td><td>7</td></tr><tr><td>22</td><td>4-F-Ph</td><td>H</td><td>48 (300 nM)</td><td>NT</td><td>72</td><td>NT</td><td>18</td></tr><tr><td>23</td><td>4-CF<sub>3</sub>-Ph</td><td>H</td><td>NT</td><td>NT</td><td>63</td><td>NT</td><td>34</td></tr><tr><td>24</td><td>4-iPr-Ph</td><td>H</td><td>38 (300 nM)</td><td>NT</td><td>65</td><td>NT</td><td>14</td></tr><tr><td>25</td><td>3,4-diF-Ph</td><td>H</td><td>NT</td><td>NT</td><td>56</td><td>124</td><td>18</td></tr><tr><td>26</td><td>3,4-diCl-Ph</td><td>H</td><td>NT</td><td>NT</td><td>70</td><td>58</td><td>12</td></tr><tr><td>27</td><td>2,5-diF-Ph</td><td>H</td><td>32 (300 nM)</td><td>NT</td><td>88</td><td>9</td><td>4</td></tr><tr><td>28</td><td>1-naphthyl</td><td>H</td><td>NT</td><td>NT</td><td>95</td><td>18</td><td>14</td></tr><tr><td>ondansetron</td><td></td><td></td><td>NT</td><td>pA<sub>2</sub> = 7.11</td><td>1</td><td>58 220</td><td>NT</td></tr><tr><td>intepirdine</td><td></td><td></td><td>NT</td><td>NT</td><td>NT</td><td>1.2</td><td>1.4</td></tr></tbody></table>

<sup>a</sup>Percent inhibition of response to stimulation by 5-HT (contraction of guinea pig ileum) at the concentration of 3 µM induced by different concentrations of test compounds shown in brackets (N = 6–8, SEM ≤ 12%). <sup>b</sup>Antagonist potency expressed as pD<sub>2</sub>' or pA<sub>2</sub> (N = 6–8, SEM ≤ 0.19). <sup>c</sup>Percent inhibition of control agonist (5-HT) response at 10<sup>-6</sup> M; performed in duplicate in 1321N1 cells. <sup>d</sup>Mean K<sub>b</sub> values based on two independent experiments in 1321N1 cells (SEM ≤ 22%). <sup>e</sup>Mean K<sub>i</sub> values based on three independent binding experiments (SEM ≤ 15%).

<figure><img src="image_20.png" /><figcaption>Table 4. Binding Data of Compounds Selected from the Synthesized Library for 5-HT<sub>6</sub>, 5-HT<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>7</sub>, and D<sub>2</sub>Rs Suggest Marginal Affinity toward 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>7</sub>, and Dopamine D<sub>2</sub> Receptors</figcaption></figure>

<table><thead><tr><th rowspan="2">compound</th><th rowspan="2">Ar</th><th rowspan="2">R</th><th colspan="6">K<sub>i</sub> [nM]<sup>a</sup></th></tr><tr><th>5-HT<sub>6</sub>R</th><th>5-HT<sub>3</sub>R</th><th>5-HT<sub>1A</sub>R</th><th>5-HT<sub>2A</sub>R</th><th>5-HT<sub>7</sub>R</th><th>D<sub>2</sub>R</th></tr></thead><tbody><tr><td>17 (FPPQ)</td><td>3-F-Ph</td><td>H</td><td>3</td><td>0.93<sup>b</sup></td><td>437</td><td>3005</td><td>2997</td><td>4392</td></tr><tr><td>18</td><td>3-Cl-Ph</td><td>H</td><td>3</td><td>NT</td><td>773</td><td>1666</td><td>1794</td><td>1345</td></tr><tr><td>20</td><td>3-Me-Ph</td><td>H</td><td>3</td><td>NT</td><td>760</td><td>4631</td><td>4139</td><td>2156</td></tr></tbody></table>

<sup>a</sup>Mean K<sub>i</sub> values (SEM ≤ 22%) based on at least three independent binding experiments. <sup>b</sup>Performed at Eurofins.

channels (K<sub>i</sub> = 0.94 µM) which are responsible for prolongation of the QT interval.

The lack of off-target-related adverse effects observed with the currently available antipsychotics, such as sedation, hyperprolactinemia, obesity, and a propensity to induce tardive dyskinesia, might be an additional benefit of dual-acting 5-HT<sub>3</sub>R/5-HT<sub>6</sub>R antagonists.

Since 5-HT<sub>6</sub>R displays a high level of constitutive activity, defined as the ability of the receptor to adopt an active conformation that enables signal transduction in the absence of an agonist, 5-HT<sub>6</sub>R ligands can be classified as inverse agonists

or neutral antagonists.<sup>39</sup> Evaluation of the impact of FPPQ on agonist-independent 5-HT<sub>6</sub>R-operated Gs signaling was performed in NG108-15 cells transiently expressing 5-HT<sub>6</sub>Rs, a cellular model in which 5-HT<sub>6</sub>R exhibits a high level of constitutive activity.<sup>18,40</sup> FPPQ did not significantly change the level of cAMP, which indicates its neutral antagonist properties toward this signaling pathway (Figure 5). Thus, FPPQ behaves similarly to CPPQ, a reference neutral antagonist of 5-HT<sub>6</sub>R.<sup>29</sup> On the other hand, SB399885 and intepirdine, the reference 5-HT<sub>6</sub>R antagonists, strongly decreased basal cAMP level in a concentration-dependent manner and thus behaved as inverse
<table><caption>**Table 5. Affinity of FPPQ for Receptors, Transporters, and Ion Channels Selected from Selectivity Profiling Panel, Compared with Its Affinities at 5-HT₃R and 5-HT₆R Main Targets, Suggest Decent Selectivity of FPPQ Compound**</caption><thead><tr><th>assay<sup>a</sup></th><th>K<sub>i</sub> [µM]</th></tr></thead><tbody><tr><td>5-HT<sub>3</sub></td><td>0.00093<sup>b</sup></td></tr><tr><td>5-HT<sub>6</sub></td><td>0.003<sup>b</sup></td></tr><tr><td>α<sub>2A</sub></td><td>0.11</td></tr><tr><td>5-HT<sub>2B</sub></td><td>0.17</td></tr><tr><td>β<sub>1</sub></td><td>0.17</td></tr><tr><td>D<sub>3</sub></td><td>0.21</td></tr><tr><td>H<sub>1</sub></td><td>0.22</td></tr><tr><td>Ca<sup>+</sup>2 channel L-type, dihydropyridine</td><td>0.50</td></tr><tr><td>Na<sup>+</sup> channel, site 2</td><td>0.71</td></tr><tr><td>5-HT<sub>2C</sub></td><td>0.83</td></tr><tr><td>5-HT<sub>1B</sub></td><td>0.89</td></tr><tr><td>hERG</td><td>0.94</td></tr><tr><td>Ca<sup>+</sup>2 channel L-type, benzothiazepine</td><td>1.08</td></tr><tr><td>DAT</td><td>1.09</td></tr><tr><td>NET</td><td>1.24</td></tr><tr><td>Ca<sup>+</sup>2 channel L-Type, phenylalkylamine</td><td>1.32</td></tr><tr><td>M<sub>1</sub></td><td>1.94</td></tr><tr><td>5-HT<sub>5A</sub></td><td>2.87</td></tr><tr><td>μ (OP3, MOP)</td><td>2.88</td></tr><tr><td>κ (OP2, KOP)</td><td>3.27</td></tr><tr><td>σ<sub>1</sub></td><td>3.50</td></tr><tr><td>α<sub>2B</sub></td><td>4.61</td></tr></tbody></table>

<sup>a</sup>Items meeting criteria of significance (≥50% stimulation or inhibition at 10 µM). For the results of all enzyme and radioligand binding assays, see Supporting Information Table S2. <sup>b</sup>See Table 4.

<figure><img src="image_21.png" /><figcaption>**Figure 5.** Influence of FPPQ, CPPQ, SB399885, and intepirdine on 5-HT₆R constitutive activity at Gs signaling in NG108-15 cells. NG108-15 cells transiently expressing the 5-HT₆R and the cAMP BRET sensor CAMYEL were exposed to increasing concentrations of SB399885, intepirdine, CPPQ, or FPPQ for 5 min. Cyclic AMP levels were estimated by measuring the CAMYEL BRET signal. Data are mean ± SEM of the values obtained in three independent experiments performed in quadruplicate using different sets of cultured cells. The BRET observed with the highest concentration of FPPQ is not significantly different from basal BRET (*p* = 0.1226, unpaired t test. ***p* < 0.01, ****p < 0.0001 vs vehicle (ANOVA followed by Dunnett's multiple comparison test).</figcaption></figure>

agonists at Gs signaling (IC₅₀ equals 97 nM and 2.8 nM for SB399885 and intepirdine, respectively).

Moreover, FPPQ did not prevent neurite growth elicited by 5-HT₆R expression in NG108-15 neuroblastoma cells, a process that is mediated by agonist-independent activation of Cdk5 signaling. In contrast, intepirdine reduced NG108-15 cell

neurite length and thus behaved as an inverse agonist at Cdk5 signaling elicited by constitutively active 5-HT₆R (Figure 6).

<figure><img src="image_22.png" /><figcaption>**Figure 6.** Effects of FPPQ (1 µM), intepirdine (1 µM), and DMSO (Vehicle) on neurite length in NG108-15 cells transfected with a plasmid encoding a GFP-tagged 5-HT₆R. The histogram shows the mean + SEM of neurite length in each condition measured from three independent experiments. Symbols: ***p* < 0.001 vs cells expressing 5-HT₆R and treated with DMSO (Vehicle). Scale bar, 10 µm.</figcaption></figure>

Both neutral antagonists and inverse agonists of 5-HT₆R have been in clinical trial for alleviating cognitive symptoms of schizophrenia. Post-mortem analysis of brains of patients with schizophrenia showed decreased levels of Cdk5 and its activator p35, suggesting a reduced Cdk5 activity in the disease.⁴¹ Accordingly, developing neutral 5-HT₆R antagonists such as FPPQ that do not inhibit Cdk5 signaling might be of greater interest than inverse agonists due to presumably less pronounced side effects linked to reduction of agonist-independent, 5-HT₆R-operated Cdk5 signaling.

**Preliminary Assessment ADME Properties as well as Safety of FPPQ.** With a molecular weight of 410.47 Da, a clogP of 4.20, a PSA of 67.23 Å², one hydrogen bond donor, three H-bond acceptors, and two rotatable bonds, the calculated descriptors confirmed the CNS druglike properties of compound FPPQ.⁴²,⁴³ Its physicochemical properties include a basic pKₐ of 8.78, indicating that this compound would be partially protonated at physiological pH. The aqueous solubility of FPPQ is high (1.4. mmol/mL at pH 7.0). FPPQ is chemically stable at both pH 1.2 and 8.0, which reflects the pH range along the gastrointestinal tract. FPPQ shows metabolic stability in both rat liver microsomes (12.8 µL/min/mg) and in human microsomes (8.2 µL/min/mg, Table 6).

To examine the propensity of potential drug-drug interactions, the inhibitory activity of FPPQ against cytochrome P450 (CYP) isoenzymes predominantly engaged in drug biotransformation was tested. FPPQ did not inhibit CYP2C9 and CYP2D6 (below 25% inhibition at 10 µM), and
<table><caption>**Table 6.** FPPQ Displays Decent Metabolic Stability and Weakly Interacts with Cytochrome P450 Isozymes</caption><thead><tr><th>assay type</th><th>FPPQ</th></tr></thead><tbody><tr><td>solubility [mmol/ml]</td><td>1.4</td></tr><tr><td>microsomal stability [CL<sub>int</sub> µL/min/mg]</td><td>rat 12.8<br>human 8.2</td></tr><tr><td>cytochrome P450 inhibition</td><td>1A2 12 µM<br>2C19 10 µM<br>3A4 57 µM<br>2C9 &lt;25% inh at 10 µM<br>2D6 &lt;25% inh at 10 µM</td></tr></tbody></table>

had moderate inhibitory activity against CYP1A2, CYP2C19, and CYP3A4 (Table 5). Moreover, FPPQ showed no mutagenic potential in the Salmonella mutagenic test, which further confirmed its safety profile (Supporting Information Table S3).

**Preliminary In Vivo Pharmacokinetics of FPPQ.** To investigate the pharmacokinetics of FPPQ in vivo, we determined its plasma and brain concentrations at various time points after oral administration (1, and 3 mg/kg) in male Lister hooded rats. FPPQ reached its maximal concentration ($C_{max}$ = 0.22 µM, and $C_{max}$ = 0.37 µM, for doses 1 and 3 mg/kg, respectively) in plasma and brain between 3 and 5 h after drug administration, regardless of the dose used, suggesting that at these doses, the compound could easily affect its main (5-HT₃R and 5-HT₆R) brain targets. FPPQ showed good brain penetration, with the concentration varying proportionally to the injected dose. The brain/plasma ratio was 2.1 ± 0.1 considering all analyzed samples (mean ± SEM, n = 36). At both doses, the levels of FPPQ in the plasma and brain decreased between 5 and 32 h post-injection, indicating that accumulation in the brain upon repeated dosing at similar dose levels is unlikely (Figure 7).

**Antipsychotic and Proognitive Properties.** Psychotomimetic compounds such as uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists (i.e., ketamine and PCP) induce schizophrenia-like symptoms in healthy volunteers and their administration to rodents serves as a model of psychosis.⁴⁴ First- and second-generation antipsychotic med-

ications with dopamine D₂ and 5-HT₂AR antagonism prevent PCP-induced increase in locomotor activity.⁴⁵

We first examined the ability of FPPQ to affect PCP-induced hyperactivity in male Sprague-Dawley rats. The wildly used antipsychotic clozapine was used as a “positive” control. Neither FPPQ nor clozapine affected spontaneous activity analyzed with the use of Area Under the Curve (AUC) on -25 to 0 min before PCP administration, suggesting no sedative effects in the present experimental conditions (Figure 8B, $F(4,50)=0.5951$, NS).

As expected, PCP administration significantly increased locomotor activity (Figure 8A). Mixed-design ANOVA with treatment as between-subject factor and time as repeated factor revealed that treatment affected PCP-induced hyperactivity during 0-120 min following PCP administration (time × treatment interaction: $F(92,1150)=2.184; p < 0.05$).

Detailed analysis of the AUC activity data measured for the 0–60 and 65–120 min post-PCP treatment periods revealed that during the initial 0–60 min, treatment affected activity ($F(4,50)=4.063; p < 0.01$) and that FPPQ decreased PCP-induced hyperactivity at both doses (1 and 3 mg/kg) while clozapine at the same doses appeared to be ineffective (Figure 8C). During the second hour following PCP administration, treatment also affected activity ($F(4,50)=4.125; p < 0.01$) and both FPPQ and clozapine decreased PCP-induced hyperactivity at 1 and 3 mg/kg (Figure 8D).

Since clozapine acts as an antagonist at both 5-HT₃ and 5-HT₆Rs, we hypothesized that simultaneous blockade of these serotonin receptors might be responsible for the “anti-PCP” effects observed for FPPQ. We thus examined more directly whether dual 5-HT₆R and 5-HT₃R antagonistic activity as presented by FPPQ and by clozapine, could produce antipsychotic-like activity.

To this end, we first assessed the effects of SB399885, a 5-HT₆R antagonist (which behaves as inverse agonist) alone on PCP-induced hyperactivity. It is known that the 5-HT₆R antagonists produce no consistent antipsychotic-like effects, and could even potentiate amphetamine-induced hyperactivity.⁴⁶ The goal of this experiment was to establish whether in PCP conditions the compound would produce similar or different effects.

<figure><img src="image_23.png" /><figcaption>**Figure 7.** Pharmacokinetic study displays sufficient plasma and brain concentration following oral administration in rats. Data show the concentration (ng/mL) of FPPQ in the plasma (A) and brain (B) of rats at different time points (in hours, h) after the administration of the drug at two doses and are expressed as mean ± SEM (N = 3 per each time point).</figcaption></figure>
<figure><img src="image_24.png" /></figure>

<figure><img src="image_25.png" /></figure>

<figure><img src="image_26.png" /></figure>

<figure><img src="image_27.png" /><figcaption>**Figure 8.** Effects of FPPQ and clozapine on PCP-induced hyperactivity (0–120 min following PCP administration) (A). Panel (B) shows no effects on spontaneous locomotor activity (−25 to 0 min before PCP administration) suggesting that neither the FPPQ compound nor clozapine produced sedative action at comparable doses. However, FPPQ but not clozapine attenuated PCP-induced hyperactivity at the 1st hour following PCP administration (C), while both compounds were active at the 2nd hour following PCP administration (D). Values present mean ± SEM of 5 min epochs (A) or the area under the curve (AUC; B, C, D). Symbols: \*p < 0.05 \*\*p < 0.01 vs vehicle+PCP (Veh), Dunnett's post hoc test. For each group, *N* = 11 rats.</figcaption></figure>

Figure 9A shows robust hyperactivity due to PCP administration. Mixed-design ANOVA demonstrated not significant interaction between time and SB399885 dose ($F(69,943) = 0.632$; NS) but significant effects of SB399885 dose ($F(3,41)=3.467$; *p* = 0.025). Analysis of the AUC at times -25 to 0 min (i.e., 30–60 min following SB399885 administration) revealed effects of treatment on spontaneous activity ($F(3,41) = 8.079$, *p* < 0.001) and its inhibition by SB399885 at 9 mg/kg, suggesting sedative-like action (Figure 9B).

Detailed analyses of SB399885 actions with the use of AUCs (Figure 9C,D) revealed however that this 5-HT₆R antagonist did not affect PCP-induced hyperactivity. While ANOVA demonstrated that the treatments affected activity at the 1st hour ($F(3,41)=3.907$, *p* < 0.05), Dunnett's post hoc test demonstrated no significant differences vs. vehicle. ANOVA for the 2nd hour was insignificant: $F(3,41) = 2.140$, *p* = 0.10.

Based on the results of this experiment, we attempted to examine the effects of a joint administration of the 5-HT₆R antagonist SB399885 and 5-HT₃R antagonist ondansetron on PCP-induced hyperactivity. The dose of SB399885 compound was set at 1 mg/kg as it certainly did not inhibit PCP hyperactivity (and even, insignificantly enhanced it, Figure 9A); see elsewhere.<sup>47,48</sup> The dose of ondansetron (0.5 mg/kg) was chosen based on Pehrson et al.<sup>49</sup> work and on du Jardin et al.,<sup>50</sup> suggestion implicating that at 1.6 mg/kg, ondansetron is expected to produce 60% or greater occupancy at the 5-HT₃R. We thus decided to use 0.5 mg/kg dose that would likely occupy ~30% of 5-HT₃R.

As shown in Figure 10B, neither SB399885 at 1 mg/kg nor ondansetron at 0.5 mg/kg affected spontaneous activity ($F(3,34) = 0.07$, NS). However, inspection of the raw data (Figure 10A) suggested that while inhibition of 5-HT₆Rs appears to enhance PCP-induced hyperactivity, the inhibition of 5-HT₃Rs likely reduces it. Mixed-design ANOVA with the time as repeated factor and the treatment with both compounds as between-subject factors on the raw data presented in Figure 10B revealed significant effects of time ($F(23,782) = 23.9443$; *p* < 0.001), an interaction between time and ondansetron ($F(23,782) = 1.9318$; *p* < 0.01), an interaction between time and SB399885 ($F(23,782)=2.2029$, *p* < 0.001), but no interaction between time, ondansetron, and SB399885: ($F(23,782) = 0.6881$, NS).

As the a priori hypothesis was that the combined treatment with 5-HT₆R and 5-HT₃R antagonists would produce different effects than their individual actions and/or vehicle, we analyzed the SB399885-induced potentiation of PCP hyperactivity and its inhibition by ondansetron addition, using analyses of contrast coefficients<sup>51</sup> on time-collapsed AUC data. These planned comparisons revealed that 5-HT₆R antagonist enhanced hyperactivity was reduced in ondansetron +SB399885 group (Figure 10C).

While these results do not provide evidence that the co-administration of ondansetron with SB399885 produces antipsychotic-like effect, they do suggest that combined administration of antagonists of both 5-HT₆R and 5-HT₃R could alleviate 5-HT₆R antagonist-induced potentiation of PCP-induced hyperactivity.
<figure><img src="image_28.png" /></figure>

<figure><img src="image_29.png" /></figure>

<figure><img src="image_30.png" /></figure>

<figure><img src="image_31.png" /></figure>

**Figure 9.** Effects of 5-HT<sub>6</sub>R antagonist SB399885 on spontaneous locomotor activity (-25 to 0 min before PCP administration) (B) and on PCP-induced hyperactivity (0–120 min following PCP administration) (A) suggest that the SB399885 compound at the highest dose of 9 mg/kg inhibited spontaneous activity. Pretreatment with SB399885 compound affected PCP-induced hyperactivity neither at the first (C) nor at the second (D) hour following PCP administration. Data are expressed as mean ± SEM of 5 min epochs (A) and mean ± SEM of the area under curve; (AUC; B, C, D). For each group, N = 15–10 rats. Symbols: \*\*\*p < 0.001, Dunnet's post hoc test vs. vehicle.

Finally, we assessed the interaction between another 5-HT<sub>6</sub>R antagonist CPPQ (which behaves as a neutral antagonist) and ondansetron on hyperactivity evoked by PCP. The dose of ondansetron (0.5 mg/kg) was the same as in the previous experiment while the doses of CPPQ (0.3, 1, and 3 mg/kg) were based on the previous report.<sup>29</sup>

Analysis of the AUC at times -25 to 0 min (i.e., 30–60 min following CPPQ and ondansetron administration) revealed effects of treatment on spontaneous activity (F(6,49) = 3.920, *p* = 0.003) and its inhibition by CPPQ at 3 mg/kg, suggestive of sedative-like action of this dose (Figure 11A,B). Thus, data of the 3 mg/kg CPPQ group were not taken for further analyses.

Figure 11A shows robust hyperactivity due to PCP administration. Two-way ANOVA on 0–120 min AUC post-PCP activity data with CPPQ dose and ondansetron as between-subject factors revealed no effects of ondansetron (F(1,43)=2.153; NS), CPPQ dose (F(2,43)=2.864; *p* = 0.068), nor their interaction (F(2,43)=0.184; NS).

However, as the a priori hypothesis was that the combined treatment with 5-HT<sub>6</sub>R and 5-HT<sub>3</sub>R antagonists would produce different effects than their individual actions and/or vehicle, we analyzed 0–120 min AUC activity data with contrast coefficients. These planned comparisons revealed that combined treatment with CPPQ (0.3 mg/kg) and ondansetron (0.5 mg/kg) inhibited PCP-induced hyperactivity compared with vehicle (Figure 11C). Of note, CPPQ alone *per se* did not increase activity, in contrast to SB399885 (see Figure 10C).

A large body of evidence had indicated that cognitive impairment is a pervasive and core pathological component of schizophrenia. Consequently, cognitive impairments have become a high-priority area in antipsychotic development. To evaluate the impact of the investigated compounds on cognitive processes, the novel object recognition (NOR) task is one of the most frequently used models.<sup>52,53</sup> In this test, FPPQ dose-dependently prevented PCP-induced short-term memory deficits when administered 30 min before PCP. The effects of FPPQ were similar to those produced by the 5-HT<sub>6</sub>R antagonist intepirdine (F(5,38) = 23.98; *p* < 0.0001; Figure 12) and by other 5-HT<sub>6</sub>R antagonists in other reports.<sup>29,54</sup>

It is also worth noting that the selective 5-HT<sub>3</sub>R antagonist ondansetron produced a procognitive effect in the NOR task,<sup>50</sup> and also showed positive results on cognitive impairment in phase II clinical trials.<sup>13</sup> In addition, the procognitive effect of the antidepressant drug vortioxetine results from its antagonistic properties at 5-HT<sub>3</sub>R in the GABAergic interneurons of the mPFC.<sup>55,56</sup> Therefore, blockade of both 5-HT<sub>3</sub>R and 5-HT<sub>6</sub>R may contribute to the procognitive effect of FPPQ.

## CONCLUSIONS

Currently used treatments for schizophrenia can effectively control positive symptoms but with some exceptions they display a limited impact on cognitive deficits. Among serotonin receptors subtypes, the 5-HT<sub>2A</sub>R is a clinically validated target. Recent attention has been paid to 5-HT<sub>3</sub>R antagonists to support available treatments. Indeed, ondansetron, an antie-metic 5-HT<sub>3</sub>R antagonist revealed positive effects as adjunctive
<figure><img src="image_32.png" /><figcaption>**Figure 10.** Effects of joint administration of the 5-HT<sub>6</sub>R antagonist SB399885 (1 mg/kg) and of the 5-HT<sub>3</sub>R antagonist ondansetron (0.5 mg/kg) on spontaneous locomotor activity (-25 to 0 min before PCP administration) (B) and on activity 0–120 min following PCP administration (A) suggest that neither compound affected spontaneous activity. (C) Pretreatment with SB399885 compound enhances PCP-induced hyperactivity compared with vehicle, and this enhancement is reduced by joint SB399885 and ondansetron administration. Symbols: \*t(68)=2.179; *p* < 0.05 vs vehicle, \#t(68)=2.158; \* *p* < 0.05 vs SB399885 only group, planned comparisons. Data are expressed as mean +, − or ± SEM of 5 min epochs (A) or the mean ± SEM of the AUC. For each group, the *N* = 9–10 rats.</figcaption></figure>

therapy of schizophrenia,<sup>12,57</sup> ameliorating both negative
symptoms and cognitive decline in patients. In parallel, 5-
HT<sub>6</sub>R antagonists have emerged as promising tools to treat
cognitive impairment. Specifically, both neutral antagonists and
inverse agonists of 5-HT<sub>6</sub>R produce procognitive effects in
preclinical and clinical settings.<sup>24,58</sup> It is worth noting that
neither 5-HT<sub>3</sub>R antagonists nor 5-HT<sub>6</sub>R antagonists improve
the positive symptoms of psychoses, a feature that is also not
addressed by antipsychotics with D<sub>2</sub> receptor component. Our
hybridization strategy proved to be successful in optimizing
first-in-class dual-acting 5-HT<sub>3</sub>R/5-HT<sub>6</sub>R antagonist and
extended the concept of rational multitarget drug discovery.
Among the evaluated series, FPPQ displayed balanced low-
nanomolar affinity at both receptors, behaved as a 5-HT<sub>3</sub>R
antagonist and a neutral antagonist at 5-HT<sub>6</sub>R-dependent Gs
signaling and had no influence on receptor-operated Cdk5-
dependent neurite growth. FPPQ showed favorable selectivity
over 87 targets, decent brain penetration, and safety profile,
with no propensity to evoke off-target-related side effects.
Ultimately, FPPQ reversed PCP-induced hyperactivity and
displayed procognitive properties in the NOR task. Though
respective contribution of blockade of 5-HT<sub>3</sub>R and 5-HT<sub>6</sub>R in
antipsychotic-like effects of FPPQ remains to be established,
these findings corroborate that combination of 5-HT<sub>3</sub>R
antagonism and 5-HT<sub>6</sub>R antagonism, exemplified by FPPQ

contribute to the effect observed in PCP-induced hyperactivity.
Development of 5-HT₃/5-HT₆R antagonists represents a
promising approach to respond to the persistent demand for
higher efficacy and better compliance in treating drug-resistant
schizophrenia symptoms.

■ EXPERIMENTAL SECTION

**Synthesis General Information.** The synthesis was carried out at ambient temperature, unless indicated otherwise. Organic solvents (from Sigma-Aldrich and Chempur) were of reagent grade and were used without purification. All reagents (Sigma-Aldrich, Fluorochem) were of the highest purity. Column chromatography was performed using silica gel Merck 60 (70–230 mesh ASTM). The UPLC purity of final compounds was verified by UV spectra and all compounds were confirmed to be ≥95% pure. Mass spectra were recorded on a UPLC-MS/MS system consisted of a Waters ACQUITY UPLC (Waters Corporation, Milford, MA) coupled to a Waters TQD mass spectrometer with electrospray ionization mode ESI-tandem quadrupole (for more information, see the Supporting Information). High-resolution MS measurements were carried out on a Bruker Impact II mass spectrometer (Bruker Corporation, Billerica). ¹H NMR and ¹³C NMR spectra were recorded using JEOL JNM-ECZR500 RS1 (ECZR version) at 500 and 126 MHz, respectively, as well as Varian BB 200 spectrometer at 300 and 75 MHz, and are reported in ppm using deuterated solvent for calibration (CDCl₃, methanol-*d*₄ or DMSO-*d*₆). The *J* values are given in Hertz (Hz). Elemental analysis for C, H, N, and S was performed on the elemental Vario EI III Elemental
<figure><img src="image_33.png" /><figcaption>**B** Effects on spontaneous activity: AUC (-25-0')</figcaption></figure>

<figure><img src="image_34.png" /><figcaption>**C** Effects on PCP-induced hyperactivity: AUC (0-120')</figcaption></figure>

<figure><img src="image_35.png" /></figure>

**Figure 11.** Effects of joint administration of 5-HT₆R antagonist CPPQ and of 5-HT₃R antagonist ondansetron on PCP-induced hyperactivity. (A) Mean – SEM raw data in 5 min epochs. (B) Mean ± SEM AUC spontaneous locomotor activity (–25 to 0 min before PCP administration) and 3 mg/kg CPPQ dose inhibited spontaneous activity (*p* < 0.05 vs vehicle, Dunnet's post hoc test); this group was not included in the final analyses. (C) Mean ± SEM 0-120 min following PCP administration AUC activity data; their analysis with contrast coefficients revealed that combined treatment with CPPQ (0.3 mg/kg) and ondansetron (0.5 mg/kg) inhibited PCP-induced hyperactivity compared with vehicle (*t*(43) = 2.430; *p* = 0.019, planned comparisons test). For each group, *N* = 7–9 rats.

<figure><img src="image_36.png" /></figure>

**Figure 12.** Effects of FPPQ on PCP-induced cognitive deficits in the NOR task suggest that like intepirdine, FPPQ prevents learning impairment and displays decent in vivo effects following oral administration in rats. Orally administered FPPQ and intepirdine (SB-742457) 30 min before PCP prevented memory deficits induced by phencyclidine (PCP, 5 mg/kg; *N* = 6–8 rats/group). Data are expressed as mean ± SEM of the discrimination index and drug doses, expressed as mg/kg, are shown in the legend below the abscissa. Symbols: VEH, vehicle; INT, intepirdine; PCP, phencyclidine; ***p < 0.001 vs control (VEH/VEH), #p < 0.05; ##p < 0.01 vs VEH/PCP, Tukey's multiple comparison post hoc test.

Analyser (Hanau, Germany). All values are reported as percentages, and were within ±0.4% of the calculated values.

Compounds 1–4 were obtained according to the previously reported procedure and the analytical data are in accordance with the literature.⁵⁹

### General Procedure for Preparation of Compounds 5a–5b.

Compound 4 (0.35 g, 1.7 mmol, 1 equiv) was dissolved in acetonitrile followed by addition of amine (1.26 g, 6.8 mmol, 4 equiv). The reaction was heated in a microwave at 140 °C for 5h. The solvent was evaporated, and the crude product was purified by chromatography using silica gel with CH₂Cl₂/MeOH 9/1.5 (v/v) as a developing solvent.

tert-Butyl-(S)-3-((1H-pyrrolo[3,2-c]quinolin-4-yl)amino)-pyrrolidine-1-carboxylate (5a). Pale oil, 60% yield, *t*<sub>R</sub> = 4.38, C₂₀H₂₄N₄O₂, MW 352.43. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 1.42 (s, 9H), 1.92–2.11 (m, 1H), 2.29–2.4 (m, 1H) 3.31–3.62 (m, 4H), 3.70–3.79 (m, 1H), 4.92 (bs, 1H), 6.54 (d, *J* = 3.1 Hz, 1H), 7.12 (d, *J* = 3.1 Hz, 1H), 7.12–7.23 (m, 1H), 7.36 (s, 1H), 7.77 (d, *J* = 8.5 Hz, 1H), 7.81 (dd, *J* = 7.8, *J* = 1.3 Hz, 1H). Monoisotopic mass 352.19, [M + H]⁺ 353.2. HRMS calculated for C₂₀H₂₅N₄O₂, 353.1978, found, 353.1978.

tert-Butyl-3-((1H-pyrrolo[3,2-c]quinolin-4-yl)amino)azetidine-1-carboxylate (5b). Pale oil, 53% yield, *t*<sub>R</sub> = 4.21, C₁₉H₂₂N₄O₂, MW 338.41. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 1.22 (s, 9H), 1.28–1.41 (m, 2H), 4.40–4.46 (m, 2H), 4.48–4.56 (m, 1H), 6.80–6.87 (m, 1H), 7.08–7.12 (d, 1H), 7.21–7.26 (m, 1H), 7.28–7.32 (m, 1H), 7.42 (bs, 1H), 8.12–8.16 (m, 1H). Monoisotopic mass 338.12, [M + H]⁺ 339.1.

### General Procedure for Preparation of Compounds 5c–5f.

Compound 4 (0.35 g, 1.7 mmol, 1 equiv) was suspended in a mixture of toluene (30 mL) and TEA (1.4 mL, 10.2 mmol, 6 equiv). Subsequently, an appropriate amine (2.4 mmol, 2 equiv, 0.27 mL)
was added and the reaction was heated at 114 °C for 14 h. The reaction mixture was evaporated, and the remaining crude product was purified by chromatography on silica gel using CH₂Cl₂/MeOH 9/1 (v/v) as a developing solvent.

**tert-Butyl (1-(1H-pyrrolo[3,2-c]quinolin-4-yl)pyrrolidin-3-yl)-(methyl)carbamate (5c).** Pale oil, 61% yield, t<sub>R</sub> = 4.88, C₂₁H₂₆N₄O₂, MW 366.47. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 1.09 (s, 3H), 1.52 (s, 9H), 2.10–2.40 (m, 3H), 4.09–4.21 (m, 4H), 6.85–6.93 (m, 1H), 7.02–7.09 (m, 1H), 7.21–7.25 (m, 1H), 7.34–7.41 (m, 1H), 7.68–7.75 (m, 1H), 7.89–8.10 (m, 1H). Monoisotopic Mass 366.21, [M + H]<sup>+</sup> 367.3.

**4-(4-Methylpiperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline (5d).** Pale oil, 62% yield, t<sub>R</sub> = 1.48, C₁₆H₁₈N₄, MW 266.34. ¹H NMR (500 MHz, CDCl₃) δ (ppm) 2.35 (s, 3H), 2.51–2.61 (m, 4H), 3.81–3.92 (m, 4H), 6.62 (s, 1H), 7.12–7.24 (m, 2H), 7.25–7.40 (m, 1H), 7.75–7.80 (m, 2H), 9.77 (bs, 1H). ¹³C NMR (126 MHz, methanol-d₄) δ ppm 42.5, 46.2, 52.6, 106.3, 108.9, 114.1, 118.6, 121.0, 126.1, 126.2, 129.6, 133.4, 138.6, 150.6. Monoisotopic Mass 266.15, [M + H]<sup>+</sup> 267.2. HRMS calcd for C₁₆H₁₉N₄ 267.160, found: 267.160.

**4-(Piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline (5e).** Boc-derivative (tert-Butyl 4-(1H-pyrrolo[3,2-c]quinolin-4-yl)piperazine-1-carboxylate). Pale oil, 63% yield, t<sub>R</sub> = 4.33, C₂₀H₂₄N₄O₂, MW 352.43. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 1.50 (s, 9H), 3.52–3.75 (m, 4H), 3.76–3.92 (m, 4H), 6.65 (d, J = 3.1 Hz, 1H), 7.15–7.25 (m, 2H), 7.31–7.42 (m, 1H), 7.83–7.91 (m, 2H), 9.75 (bs, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ (ppm) 28.5, 47.7, 79.4, 103.8, 111.6, 116.3, 120.6, 122.6, 123.3, 126.7, 127.3, 136.73, 143.2, 154.5, 154.5. Monoisotopic Mass 352.19, [M + H]<sup>+</sup> 353.4. HRMS calcd for 353.1978; found 353.1977.

**Hydrochloride Salt.** White solid, 67% yield, t<sub>R</sub> = 1.40, C₁₅H₁₇ClN₄, MW 288.78. ¹H NMR (500 MHz, methanol-d₄) δ (ppm) 3.58 (bs, 4H), 4.36 (bs, 4H), 7.14 (s, 1H), 7.56–7.63 (m, 2H), 7.70 (t, J = 7.3 Hz, 1H), 8.06 (d, J = 8.3 Hz, 1H), 8.23–8.27 (m, 1H). ¹³C NMR (126 MHz, methanol-d₄) δ ppm 40.4, 42.9, 45.9, 106.4, 108.8, 114.1, 118.5, 121.0, 126.0, 126.2, 129.5, 133.3, 138.5, 150.8. Monoisotopic Mass 252.1, [M + H]<sup>+</sup> 253.2. HRMS calcd for C₁₆H₁₉N₄ 252.3210, found: 253.1456.

**tert-Butyl-4-(1H-pyrrolo[3,2-c]quinolin-4-yl)-1,4-diazepane-1-carboxylate (5f).** Pale oil, 85% yield, t<sub>R</sub> = 4.84, C₂₁H₂₆N₄O₂, MW 366.46. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 1.41 (s, 9H), 1.51–1.73 (m, 2H), 1.90–2.21 (m, 2H), 3.24–3.56 (m, 2H), 3.73 (bs, 1H), 4.01–4.34 (m, 3H), 6.70 (bs, 1H), 7.05–7.21 (m, 1H), 7.25–7.45 (m, 3H), 7.81 (t, J = 7.6 Hz, 1H). Monoisotopic Mass 366.21, [M + H]<sup>+</sup> 367.2.

**General Procedure for the Preparation of Compounds 6–28.** Compounds 5a–5f (0.28 mmol, 1 equiv) were dissolved in CH₂Cl₂ (5 mL) and BTPP (170 µL, 0.56 mmol, 2 equiv) was added. The mixture was placed in an ice bath, sulfonyl chloride (1.8 equiv) was added, and the reaction mixture was stirred for 3 h. Subsequently, the mixture was evaporated and the remaining crude product was purified by chromatography on silica gel. The Boc-protected derivatives were treated with 1 N HCl solution in MeOH to give HCl salts of secondary amines.

**1-(Phenylsulfonyl)-4-(4-methylpiperazin-1-yl)-1H-pyrrolo[3,2-c]-quinoline hydrochloride (6).** White solid, 80% yield, t<sub>R</sub> = 4.69, Mp = 127–129 °C, C₂₂H₂₃ClN₄O₂S, MW 442.96. ¹H NMR (500 MHz, methanol-d₄) δ (ppm) 3.06 (s, 3H), 3.50 (bs, 2H), 3.79 (bs, 2H), 4.04 (bs, 2H), 4.67 (bs, 2H), 7.40 (d, J = 3.7 Hz, 1H), 7.52–7.60 (m, 3H), 7.68–7.72 (m, 2H), 7.90–7.96 (m, 2H), 8.12 (d, J = 8.3 Hz, 1H), 8.29 (d, J = 4.0 Hz, 1H), 8.93–8.98 (m, 1H). ¹³C NMR (126 MHz, methanol-d₄) δ ppm 43.5, 47.8, 53.6, 109.0, 115.0, 116.7, 120.8, 125.2, 127.1, 128.3, 130.9, 131.6, 131.8, 136.6, 137.9, 138.6, 151.8. Monoisotopic mass 406.15, [M + H]<sup>+</sup> 407.3. HRMS calcd for C₂₂H₂₂N₄O₂S 407.1542; found: 407.1542.

**1-(Phenylsulfonyl)-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (7).** White solid, 90% yield, t<sub>R</sub> = 4.51, Mp 130–132 °C, C₂₁H₂₂Cl₂N₄O₂S, MW 465.40. ¹H NMR (500 MHz, methanol-d₄) δ (ppm) 3.48–3.55 (m, 4H), 4.17–4.27 (m, 4H), 7.37–7.40 (m, 1H), 7.51–7.55 (m, 3H), 7.65–7.75 (m, 2H), 7.85–7.90 (m, 2H), 8.12–8.15 (m, 1H), 8.25–8.35 (m, 1H), 8.98 (dd, J = 8.6, J = 0.9 Hz,

1H). ¹³C NMR (126 MHz, DMSO-d₆) δ ppm 42.9, 46.8, 109.0, 114.1, 116.7, 123.7, 125.5, 126.0, 127.6, 128.2, 129.9, 130.3, 130.9, 136.1, 136.5, 137.1, 152.2. Monoisotopic Mass 392.13, [M + H]<sup>+</sup> 393.3. HRMS calcd for C₂₁H₂₀N₄O₂S 393.1385; found 393.1387.

**(S)-1-(Phenylsulfonyl)-N-(pyrrolidin-3-yl)-1H-pyrrolo[3,2-c]-quinolin-4-amine dihydrochloride (8).** White solid, 80% yield, t<sub>R</sub> = 4.78, Mp 220–222 °C, C₂₁H₂₂Cl₂N₄O₂S, MW 465.39. ¹H NMR (300 MHz, methanol-d₄) δ (ppm) 2.43–2.47 (m, 1H), 2.59–2.77 (m, 1H), 3.46–3.52 (m, 2H), 3.53–4.01 (m, 2H), 5.18 (bs, 1H), 7.41–7.51 (m, 4H), 7.53–7.64 (m, 2H), 7.73–7.91 (m, 3H), 8.22 (m, 1H), 8.86 (d, J = 7.9 Hz, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ ppm 31.2, 44.2, 49.1, 52.7, 108.9, 112.9, 115.9, 120.3, 123.7, 125.6, 126.4, 127.2, 130.2, 130.7, 132.8, 134.4, 135.3, 136.1, 138.5, 148.4. Monoisotopic Mass 392.13, [M + H]<sup>+</sup> 393.1. HRMS calcd for C₂₁H₂₀N₄O₂S 392.1307, found 393.1322.

**N-(Azetidin-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]quinolin-4-amine dihydrochloride (9).** White solid, 94% yield, t<sub>R</sub> = 3.35, Mp 243–246 °C, C₂₀H₂₀Cl₂N₄O₂S, MW 451.37. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm) 4.31–4.32 (m, 1H), 4.78–5.16 (m, 4H), 6.92–6.94 (m, 1H), 7.10 (s, 2H), 7.31–7.38 (m, 4H), 7.54–7.57 (m, 1H), 7.81 (d, J = 8.3 Hz, 1H), 8.01 (d, J = 8.3 Hz, 1H), 8.20–8.22 (m, 1H). Monoisotopic Mass: 378.12, [M + H]<sup>+</sup> 379.2.

**N-Methyl-1-(1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]quinolin-4-yl)-pyrrolidin-3-amine dihydrochloride (10).** White solid, 89% yield, t<sub>R</sub> = 4.75, Mp 256–258 °C, C₂₂H₂₄Cl₂N₄O₂S, MW 479.42. ¹H NMR (500 MHz, DMSO-d₆) δ (ppm) 2.49–2.63 (m, 2H), 3.11 (s, 3H), 3.76–3.91 (m, 1H), 4.16–4.21 (m, 1H), 4.23–4.41 (m, 2H), 4.61 (m, 1H), 5.78–5.94 (m, 1H), 6.81–6.90 (m, 1H), 7.10–7.24 (m, 1H), 7.26–7.41 (m, 3H), 7.47–7.55 (m, 1H), 7.68–7.77 (m, 2H), 7.79–7.81 (m, 1H), 7.87–7.92 (m, 1H). ¹³C NMR (126 MHz, DMSO-d₆) δ ppm 29.5, 48.3, 52.3, 125.0, 126.0, 127.9, 130.9, 131.3, 132.7, 134.0. Monoisotopic Mass: 406.15, [M + H]<sup>+</sup> 407.2.

**4-(1,4-Diazepan-1-yl)-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]-quinoline dihydrochloride (11).** White solid, 95% yield, t<sub>R</sub> = 5.72, Mp 247–248 °C, C₂₂H₂₄Cl₂N₄O₂S, MW 513.87. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 2.25–2.47 (m, 2H), 3.28–3.47 (m, 2H), 3.60–3.75 (m, 2H), 4.15–4.25 (m, 2H), 4.26–4.35 (m, 2H), 6.76–6.81 (m, 1H), 7.18–7.25 (m, 1H), 7.35–7.38 (m, 1H), 7.50–7.68 (m, 3H), 7.73–7.75 (m, 1H), 7.75–7.80 (m, 1H), 8.00–8.12 (m, 1H), 8.25–8.30 (m, 1H), 8.75–8.82 (m, 1H). ¹³C NMR (126 MHz, DMSO-d₆) δ ppm 24.8, 45.1, 46.8, 110.3, 113.0, 115.5, 123.7, 126.5, 127.4, 130.0, 132.9, 135.4, 136.2, 136.5, 138.7. Monoisotopic Mass 406.14. [M + H]<sup>+</sup> 407.2.

**1-[(3-Fluorophenyl)sulfonyl]-4-(4-methylpiperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline hydrochloride (12).** White solid, 88% yield, t<sub>R</sub> = 4.95, Mp 176–177 °C, C₂₂H₂₂ClF₄N₄O₂S, MW 460.95. ¹H NMR (500 MHz, methanol-d₄) δ (ppm) 3.03 (s, 3H), 3.46 (bs, 2H), 3.70 (bs, 2H), 3.96 (bs, 2H), 4.64 (bs, 2H), 7.38 (d, J = 4.0 Hz, 1H), 7.42–7.49 (m, 1H), 7.55–7.63 (m, 2H), 7.68–7.74 (m, 3H), 8.09 (dd, J = 8.6, J = 0.9 Hz, 1H), 8.28 (d, J = 4.0 Hz, 1H), 8.93 (dd, J = 8.6, J = 0.6, 1H). ¹³C NMR (126 MHz, methanol-d₄) δ ppm 42.4, 52.4, 108.4, 113.4, 114.6, 115.8, 119.5, 122.7, 124.0, 126.2, 130.7, 132.3, 135.0, 137.6, 138.5, 150.5, 160.7, 164.1. Monoisotopic Mass 424.14, [M + H]<sup>+</sup> 425.1. HRMS calcd for C₂₂H₂₂N₄O₂S 425.1453; found 425.1450.

**1-[(3-Chlorophenyl)sulfonyl]-4-(4-methylpiperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline hydrochloride (13).** White solid, 91% yield, t<sub>R</sub> = 4.97, Mp 125–124 °C, C₂₂H₂₂Cl₂N₄O₂S, MW 477.40. ¹H NMR (500 MHz, methanol-d₄) δ (ppm) 3.03 (s, 3H), 3.38–3.61 (m, 2H), 3.63–3.78 (m, 2H), 3.81–4.18 (m, 2H), 4.52–4.68 (m, 2H), 7.39 (d, J = 4.0 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.56–7.63 (m, 1H), 7.65–7.71 (m, 1H), 7.71–7.78 (m, 1H), 7.84–7.90 (m, 1H), 7.95 (t, J = 1.9 Hz, 1H), 8.06–8.12 (m, 1H), 8.28 (d, J = 4.0 Hz, 1H), 8.93 (dd, J = 8.6, J = 0.9 Hz, 1H). ¹³C NMR (126 MHz, methanol-d₄) δ ppm 46.4, 56.5, 112.5, 117.4, 119.8, 123.4, 127.8, 129.9, 130.3, 131.0, 134.9, 135.6, 138.8, 139.5, 139.8, 141.4, 142.4, 154.6. Monoisotopic Mass 440.11, [M + H]<sup>+</sup> 441.2. HRMS calcd for C₂₂H₂₂ClN₄O₂S 441.1152; found: 441.1151.

**1-((4-Fluorophenyl)sulfonyl)-4-(4-methylpiperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline hydrochloride (14).** Yellow oil, 80% yield, t<sub>R</sub>
= 4.94, C₂₂H₂₂ClF₄N₂O₂S, MW 460.95. ¹H NMR (500 MHz, methanol-d₄) δ (ppm) 2.35 (s, 3H), 2.61–2.65 (m, 4H), 3.60–3.67 (m, 4H), 6.91–6.99 (m, 1H), 7.15–7.18 (m, 2H), 7.25–7.30 (m, 1H), 7.38–7.49 (m, 1H), 7.75–7.81 (m, 3H), 7.88–7.92 (m, 1H), 8.78 (d, *J* = 8.0 Hz, 1H). ¹³C NMR (126 MHz, DMSO-d₆) δ ppm 46.3, 48.6, 55.1, 108.4, 115.1, 117.5, 118.0, 123.1, 123.8, 128.4, 129.1, 130.9, 133.9, 136.2, 145.3, 154.8, 164.8, 166.8. Monoisotopic Mass 424.14, [M + H]⁺ 425.3. HRMS calcd for C₂₂H₂₂N₄O₂S 425.1453; found 425.1452.

1-[(2-Bromophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (15). White solid, 92% yield, t<sub>R</sub> = 4.65, Mp 158–160 °C, C₂₁H₂₁BrCl₂N₄O₂S, MW 544.29. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 3.40–3.45 (m, 4H), 4.22–4.25 (m, 4H), 7.04–7.25 (m, 2H), 7.27–7.62 (m, 4H), 7.90–8.20 (m, 2H), 8.21–8.25 (m, 1H), 8.26–8.43 (m, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ ppm 43.0, 46.8, 51.6, 109.1, 114.5, 117.3, 118.8, 121.4, 123.1, 127.2, 128.4, 130.4, 131.7. Monoisotopic Mass 470.04, [M + H]⁺ 471.2, 473.2. HRMS calcd for C₂₁H₂₀BrN₄O₂S 471.0487; found: 471.0490.

1-[(2-Chlorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (16). White solid, 92% yield, t<sub>R</sub> = 5.21, Mp 157–159 °C, C₂₁H₂₁Cl₃N₄O₂S, MW 526.92. ¹H NMR (300 MHz, methanol-d₄) δ (ppm) 3.50–3.53 (m, 4H), 4.20–4.27 (m, 4H), 7.25–7.31 (s, 1H), 7.43–7.54 (m, 2H), 7.56–7.84 (m, 2H), 7.81 (m, 1H), 7.88 (m, 1H), 8.25 (m, 1H), 8.75 (m, 1H), 8.88 (s, 1H). ¹³C NMR (75 MHz, methanol-d₄) δ ppm 42.8, 46.5, 108.5, 113.5, 115.9, 119.6, 124.1, 125.9, 127.1, 130.8, 131.6, 135.5, 135.8, 137.6, 138.5, 150.9. Monoisotopic Mass 426.09, [M + H]⁺ 427.3. HRMS calcd for C₂₁H₂₀ClN₄O₂S 427.0995; found: 427.0990.

1-[(3-Fluorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (17) FFPQ. White solid, 96% yield, t<sub>R</sub> = 4.76, Mp 192–193 °C. Anal. calcd for C₂₁H₂₁Cl₂F₄N₄O₂S × 2H₂O: C: 48.56, H: 4.85, N: 10.79, S: 6.17; found: C: 48.57, H: 5.01, N: 10.71, S: 6.11. MW 591.41. ¹H NMR (300 MHz, methanol-d₄) δ (ppm) 3.64 (t, *J* = 5.0 Hz, 4H), 4.38 (t, *J* = 5.0 Hz, 4H), 7.31–7.51 (m, 2H) 7.53–7.65 (m, 2H) 7.72–7.78 (m, 3H), 8.18–8.21 (m, 1H), 8.28–8.31 (m, 1H), 8.88–8.91 (m, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ ppm 42.8, 46.9, 109.4, 113.6, 115.2, 116.7, 119.3, 122.0, 123.6, 124.1, 125.8, 130.5, 133.4, 136.6, 137.6, 138.6, 150.7, 151.7, 160.5, 163.9. Monoisotopic Mass 410.12, [M + H]⁺ 411.1. HRMS calcd for C₂₁H₁₉FN₄O₂S 411.1296; found: 411.1292.

1-[(3-Chlorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (18). White solid, 95% yield, t<sub>R</sub> = 5.19, Mp 161–163 °C, Anal. calcd for C₂₁H₂₁Cl₃N₄O₂S: C: 50.46, H: 4.23, N: 11.21, S: 6.42; found: C: 50.85, H: 4.64, N: 11.37, S: 6.82, MW 499.84. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 3.45 (bs, 4H), 4.28 (bs, 4H), 7.19 (s, 1H), 7.25–7.51 (m, 3H), 7.56–7.61 (m, 2H), 7.68 (s, 1H), 8.00 (s, 1H), 8.29 (d, *J* = 8.5 Hz, 1H), 8.75 (d, *J* = 8.2 Hz 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ (ppm) 42.8, 46.8, 109.4, 113.7, 116.8, 123.6, 125.7, 126.4, 127.2, 130.4, 132.7, 135.3, 136.1, 138.5, 151.8. Monoisotopic Mass 426.09, [M + H]⁺ 427.0, 429.0. HRMS calcd for C₂₁H₂₀ClN₄O₂S 427.0995; found: 427.0989.

1-[(3-Trifluoromethyl)phenyl]sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (19). White solid, 92% yield, t<sub>R</sub> = 5.49, Mp 182–185 °C, C₂₂H₂₁Cl₂F₃N₄O₂S, MW 533.39. ¹H NMR (300 MHz, methanol-d₄) δ (ppm) 3.52–3.56 (m, 4H), 4.25–4.31 (m, 4H), 6.53 (m, 2H), 7.22 (m, 1H), 7.51–7.65 (m, 3H), 7.75 (t, *J* = 7.8 Hz, 1H), 8.10–8.21 (m, 2H), 9.15 (m, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ (ppm) 43.0, 46.4, 109.3, 114.6, 117.3, 122.5, 123.3, 125.2, 129.5, 130.1, 131.7, 132.6, 136.5, 138.3. Monoisotopic Mass 460.12, [M + H]⁺ 461.0. HRMS calcd for C₂₂H₂₀F₃N₄O₂S 461.1259; found: 461.1261.

1-[(3-Methylphenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (20). White solid, 80% yield, t<sub>R</sub> = 4.92, Mp 179–181 °C, C₂₂H₂₄Cl₂N₄O₂S, MW 479.42. ¹H NMR (300 MHz, methanol-d₄) δ (ppm) 2.24–2.34 (m, 3H), 3.51–3.53 (m, 4H) 4.24–4.26 (m, 4H), 7.35 (d, *J* = 3.8 Hz, 2H), 7.46–7.48 (m, *J* = 15.0, 7.4 Hz, 1H), 7.50–7.51 (m, 1H), 7.68–7.75 (m, 3H), 8.11–8.21 (m, 1H), 8.25–8.26 (m, 1H), 8.88–8.91 (m, 1H). ¹³C NMR (75 MHz, methanol-d₄) δ (ppm) 19.7, 42.7, 46.4, 107.9, 113.4, 115.4, 119.3,

124.3, 124.4, 125.9, 127.3, 129.7, 130.7, 134.9, 136.0, 136.6, 137.4, 140.8, 150.7. Monoisotopic Mass 406.15, [M + H]⁺ 407.1. HRMS calcd for C₂₂H₂₃N₄O₂S 407.1542; found: 407.1538.

1-[[(3-Methoxyphenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (21). White solid, 91% yield, t<sub>R</sub> = 4.82, C₂₂H₂₄Cl₂N₄O₃S, MW 495.42. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 3.49 (bs, 4H), 3.72 (s, 3H), 4.25 (bs, 4H), 7.18–7.25 (m, 1H), 7.27–7.30 (m, 2H), 7.36–7.41 (m, 2H), 7.52–7.59 (m, 1H), 7.68–7.75 (m, 1H), 8.09–8.12 (m, 1H), 8.24–8.27 (m, 1H), 8.96–9.00 (m, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ (ppm) 42.9, 46.8, 56.5, 109.1, 112.4, 114.1, 116.8, 119.5, 121.9, 123.8, 125.6, 130.0, 130.4, 132.2, 136.6, 138.1, 152.2, 160.3. Monoisotopic Mass 422.14, [M + H]⁺ 423.1. HRMS calcd for C₂₂H₂₂N₄O₃S 423.1491; found 423.1491.

1-[[(4-Fluorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (22). White solid, 95% yield, t<sub>R</sub> = 4.65, Mp 172–174 °C, C₂₁H₂₁Cl₂F₄O₂S, MW 483.39. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 3.41–3.47 (m, 4H), 4.27–4.35 (m, 4H), 6.98–7.21 (m, 2H), 7.23–7.26 (m, 1H), 7.41–7.48 (m, 1H), 7.54–7.64 (m, 1H), 7.70–7.82 (m, 2H), 7.98–8.05 (m, 1H), 8.24–8.34 (m, 1H), 8.75–8.80 (m, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ (ppm) 44.3, 49.3, 108.7, 113.2, 115.9, 118.4, 123.9, 131.4, 133.2, 134.5, 148.7, 157.5, 165.2, 167.2. Monoisotopic Mass 410.12, [M + H]⁺ 411.3. HRMS calcd for C₂₁H₁₉FN₄O₂S 411.1296; found 411.1293.

1-[[(4-Trifluoromethyl)phenyl]sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (23). White solid, 91% yield, t<sub>R</sub> = 5.38, Mp 165–167 °C, C₂₂H₂₁Cl₂F₃N₄O₂S, MW 533.39. ¹H NMR (300 MHz, methanol-d₄) δ (ppm) 3.50–3.59 (m, 4H), 4.25–4.37 (m, 4H), 7.30–7.33 (m, 1H), 7.53 (t, *J* = 7.8 Hz, 1H), 7.67–7.75 (t, *J* = 7.8 Hz, 1H), 7.78–7.90 (m, 2H), 8.15–8.38 (m, 3H), 8.25–8.31 (m, 1H), 8.88–8.90 (m, 1H). ¹³C NMR (75 MHz, methanol-d₄) δ (ppm) 42.7, 46.5, 108.7, 113.4, 115.9, 119.5, 123.9, 126.2, 127.1, 128.3, 130.7, 135.1, 135.8, 137.6, 140.5, 150.7. Monoisotopic Mass 460.12, [M + H]⁺ 461.3. HRMS calcd for C₂₂H₂₀F₃N₄O₂S 461.1259; found: 461.1263.

1-[[(4-iso-Propylphenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (24). White solid, 79% yield, t<sub>R</sub> = 5.62, Mp 212–214 °C, C₂₄H₂₈Cl₂N₄O₂S, MW 507.47. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 1.01–1.14 (m, 6H), 2.70–2.82 (m, 1H), 3.40–3.57 (m, 4H), 4.23–4.37 (m, 4H), 7.13–7.23 (m, 3H), 7.40 (t, *J* = 7.6 Hz, 1H), 7.51–7.68 (m, 3H), 7.98–8.02 (m, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 8.83 (d, *J* = 8.5 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃/methanol-d₄) δ (ppm) 23.2, 34.2, 43.2, 47.1, 108.3, 113.4, 115.0, 120.0, 124.0, 126.2, 127.5, 128.1, 130.7, 133.7, 134.9, 137.7, 150.1, 157.5. Monoisotopic Mass 434.18, [M + H]⁺ 435.3. HRMS calcd for C₂₄H₂₆N₄O₂S 435.1855; found: 435.1854.

1-[[(3,4-Difluorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (25). White solid, 98% yield, t<sub>R</sub> = 5.01, Mp 180–182 °C, C₂₁H₂₀Cl₃F₃N₄O₂S, MW 501.38. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 3.21–3.43 (m, 4H), 4.11–4.45 (m, 4H), 7.20–7.25 (m, 2H), 7.42–7.49 (m, 1H), 7.50–7.61 (m, 3H), 7.99 (d, *J* = 3.3 Hz, 1H), 8.31 (d, *J* = 8.0 Hz, 1H), 8.77 (d, *J* = 7.7 Hz, 1H). ¹³C NMR (75 MHz, DMSO-d₆) δ ppm 43.0, 46.5, 109.3, 117.3, 123.5, 125.5, 127.7, 129.6, 130.2, 133.1, 133.8, 136.5, 137.1, 139.4. Monoisotopic Mass 428.11, [M + H]⁺ 429.2. HRMS calcd for C₂₁H₁₉F₂N₄O₂S 429.1197; found: 429.1201.

1-[[(3,4-Dichlorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (26). White solid, 80% yield, t<sub>R</sub> = 5.63, Mp 203–205 °C, C₂₁H₂₀Cl₄N₄O₂S, MW 534.29. ¹H NMR (300 MHz, CDCl₃/methanol-d₄) δ (ppm) 3.26–3.49 (m, 4H), 4.27–4.37 (m, 4H), 7.15–7.26 (m, 1H), 7.37–7.55 (m, 3H), 7.56–7.67 (m, 1H), 7.80 (s, 1H), 7.95–8.02 (m, 1H), 8.32 (d, *J* = 8.2 Hz, 1H), 8.77 (d, *J* = 8.2 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃/methanol-d₄) δ ppm 42.7, 46.6, 108.6, 113.4, 115.4, 120.2, 123.7, 126.3, 126.6, 129.0, 130.6, 131.2, 132.0, 134.7, 135.9, 137.9, 140.7, 150.2. Monoisotopic Mass 460.05, [M + H]⁺ 461.2, 463.2. HRMS calcd for C₂₁H₁₈Cl₅N₄O₂S 461.0606; found: 461.0605.

1-[[(2,5-Difluorophenyl)sulfonyl]-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (27). White solid, 81% yield, t<sub>R</sub> =
4.75 M p 204−206 °C, C₂₁H₂₀Cl₂F₂N₄O₂S, MW 501.38. ¹H NMR (300 MHz, CDCl₃/methanol-₄d) δ (ppm) 3.24−3.55 (m, 4H), 4.31−4.37 (m, 4H), 6.98−7.12 (m, 1H), 7.13−7.25 (m, 1H), 7.25−7.38 (m, 1H), 7.40−7.45 (m, 1H), 7.50−7.67 (m, 1H), 7.75−7.80 (m, 1H), 7.99−8.12 (m, 1H), 8.36 (d, *J* = 8.2 Hz, 1H), 8.63 (d, *J* = 8.2 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ ppm 43.2, 44.3, 48.9, 53.5, 106.8, 115.2, 117.1, 119.2, 122.8, 123.9, 127.0, 128.1, 128.6, 136.5, 145.5, 154.1, 155.0, 156.7, 158.7. Monoisotopic Mass 428.11, [*M* + H]⁺ 429.2. HRMS calcd for C₂₆H₂₇F₂N₄O₄S 429.1197; found: 429.1196.

1-(Naphthalen-1-ylsulfonyl)-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline dihydrochloride (28). White solid, 86% yield, t<sub>R</sub> = 5.17, Mp 218–220 °C, C<sub>25</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S, MW 515.45. ¹H NMR (300 MHz CDCl<sub>3</sub>/methanol-<sub>4</sub>d) δ (ppm) 3.36–3.56 (m, 4H), 4.21–4.42 (m, 4H), 7.18–7.26 (m, 2H), 7.35–7.44 (d, *J* = 6.2 Hz, 1H), 7.46–7.62 (m, 3H), 7.85 (d, *J* = 7.7 Hz, 1H), 7.95–8.12 (m, 3H), 8.24 (t, *J* = 8.1 Hz, 2H), 8.60 (d, *J* = 8.7 Hz, 1H). ¹³C NMR (75 MHz, CDCl<sub>3</sub>/methanol-<sub>4</sub>d) δ ppm 42.7, 46.6, 107.6, 113.1, 114.4, 119.5, 122.4, 123.8, 124.5, 126.1, 127.5, 127.8, 129.5, 129.7, 130.4, 130.5, 130.8, 131.2, 134.0, 134.7, 137.3, 138.0, 150.1. Monoisotopic Mass 442.15, [*M* + H]⁺ 443.3. HRMS calcd for C<sub>25</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>S 443.1542; found: 443.1544.

**In Silico Simulations. Preparation of the Proteins.** The construction of the 5-HT<sub>6</sub>R homology models has been described in detail elsewhere.<sup>59</sup> The 5-HT<sub>3</sub>R co-crystallized with granisetron (PDB code 6NP0) was retrieved from the PDB database.<sup>36</sup> Protein Preparation Wizard was used to assign bond orders, appropriate amino acid ionization states, and to check for steric clashes.

**Molecular Docking.** The three-dimensional structures of the ligands were prepared using LigPrep, and the appropriate ionization states at pH 7.4 ± 1.0 were assigned using Epik v5.0. The grids were generated (OPLS3 force field) by centering the grid box with a size of 20 Å on D3.32 (in case of 5-HT<sub>6</sub>R), and on W63 (for 5-HT<sub>3</sub>R). Flexible molecular docking was performed using Glide v8.5 at the standard precision (SP) level.

**In Vitro Pharmacological Evaluation. Cell Culture and Preparation of Cell Membranes for Radioligand Binding Assays.** All of the experiments were carried out according to previously published procedures.<sup>60–62</sup> In brief, HEK293 cells with stable expression of h5-HT<sub>1A</sub>, h5-HT<sub>6</sub>, h5-HT<sub>7b</sub>, and hD<sub>2L</sub> receptors or CHO-K1 cells with a plasmid containing the sequence coding for the h5-HT<sub>2A</sub>R (PerkinElmer, # ES-313-C) were grown in Dulbecco's modified Eagle medium containing 10% dialyzed fetal bovine serum and 500 µg/mL G418 sulfate. For membrane preparation, cells after reaching 90% confluence, were washed with phosphate-buffered saline (PBS), and pelletted by centrifugation (200 × g) in PBS containing 0.1 mM EDTA and 1 mM dithiothreitol.

**Radioligand Binding Assays.** The cell pellets were homogenized in assay buffer using a tissue homogenizer (Ultra Turrax IKAT25), centrifuged twice (35 000g, 15 min, 4 °C), and incubated (15 min, 37 °C) between centrifugation rounds. The buffers used were dedicated to a given type of receptor, and their composition was the same as in previously published articles.<sup>60–62</sup> All assays were incubated in 96-well round-bottom microwell plates for 1 h at 37 °C. The exceptions were assays for 5-HT<sub>1A</sub>R and 5-HT<sub>2A</sub>R, which were performed at 24 °C and 27 °C, respectively. The total reaction volume was 200 µL. The incubation process was terminated by filtration through UniFilter-96 (PerkinElmer) plates with the FilterMate Universal Harvester (PerkinElmer, #C961962), and radioactivity retained on the filters was quantified on a MicroBeta counter for radiometric detection (PerkinElmer). For competitive studies, the assay samples contained as radioligands: 2.5 nM [³H]-8-OH-DPAT (PerkinElmer, #NET929001MC) for 5-HT<sub>1A</sub>R, 1 nM [³H]-ketanserin (PerkinElmer, #NET791250UC) for 5-HT<sub>2A</sub>R, 2 nM [³H]-LSD (PerkinElmer, #NET638250UC) for 5-HT<sub>6</sub>R, 0.8 nM [³H]-5-CT (PerkinElmer, #NET1188U100UC) for 5-HT<sub>7</sub>R, or 2.5 nM [³H]-raclopride (PerkinElmer, #NET975001MC) for D<sub>2L</sub>R. To evaluate the level of nonspecific signal 10 µM of 5-HT for 5-HT<sub>1A</sub>R and 5-HT<sub>7</sub>R, 20 µM of mianserin for 5-HT<sub>2A</sub>R, 10 µM of methiothepine for 5-HT<sub>6</sub>R and 10 µM of haloperidol for D<sub>2L</sub>R were used. Each compound was tested

in triplicate at 7 concentrations in the range from 10⁻¹⁰ to 10⁻⁴ M. The inhibition constants (Kᵢ) were obtained from the Cheng–Prusoff model.<sup>63</sup> The acquired results were presented as the mean of at least two independent experiments.

**Evaluation of Functional Activity of 5-HT<sub>6</sub>Rs.** Compounds were examined on 5-HT<sub>6</sub>R using their ability to inhibit cAMP production induced by 1 µM (EC₈₀) 5-carboxamidotryptamine (5-CT). The level of cAMP was measured in 1321N1 cells expressing the h5-HT<sub>6</sub>R (PerkinElmer, #ES-316-CF). According to the manufacturer's instructions, total cAMP was measured using the LANCE cAMP detection kit (PerkinElmer, #TRF0263). Cells were incubated with a mixture of compounds for 30 min at room temperature (RT) in a white polystyrene OptiPlate-384 (PerkinElmer, #6007299) microplate. After incubation, the reaction cells were lysed by the addition of 10 µL of cAMP detection buffer, including Eu-cAMP tracer and ULight-anti-cAMP working solution. The plate was incubated at RT for 1 h before measuring the signal with a Tecan multimode plate reader (Infinite M1000 Pro). Compounds were tested in triplicate at eight concentrations in the range from 10⁻¹¹ to 10⁻⁴ M. K<sub>b</sub> constants were calculated from Cheng–Prusoff equation<sup>63</sup> adapted to functional assays.

**Ex Vivo Evaluation of Functional Activity at 5-HT<sub>3R</sub> Functional Assay.** Isolated guinea pig ileum was employed to test the affinity and the intrinsic activity of the investigated compounds for 5-HT<sub>3</sub> receptors. The tissue was dissected from male guinea pigs previously deprived of food for 24 h but with free access to drinking water. A 15 cm ileum segment was excised from the small intestine of male guinea pigs and immersed into a Krebs solution (NaCl 120 mM, KCl 5.6 mM, MgCl₂ 2.2 mM, CaCl₂ 2.4 mM, NaHCO₃ 19 mM, glucose 10 mM). After the first 5 cm length closest to the ileocaecal junction had been discarded 2 cm-long fragments were cut. Each segment of the ileum was placed in a 20 mL chamber of tissue organ bath system (Tissue Organ Bath System – 750 TOBS, DMT, Denmark) filled with the Krebs solution at 37° C, pH 7.4, with constant oxygenation (O₂/CO₂, 19:1), fixed by the lower end to a rod and by the upper end to the force-displacement transducer. The preparation was allowed to stabilize in organ baths for 60 min under a resting tension of 0.5 g, washing every 15 min with fresh Krebs solution. After the equilibration period, a cumulative concentration-response curve was constructed in each tissue for 5-HT (10 nM – 10 µM) by the method of van Rossum.<sup>64</sup> The inhibitory effect of compounds was first evaluated by their influence (after 15 min of incubation with the tissue) on the contraction induced by single administration of 5-HT at the concentration of 3 µM and expressed as a percentage of inhibition of the maximal tension obtained with the contractile agent. Selected compounds were tested using an additional method. After establishment of the first 5-HT concentration-response curve, washing out of the tissue, and stabilization period, the same tissues were subsequently incubated with one of the concentrations of the tested compound for 15 min and the next cumulative concentration curve to 5-HT was obtained. Only one concentration of a studied compound was tested in each piece of tissue. Concentration-response curves were analyzed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA) and the antagonistic properties were expressed as pD₂' or pA₂. The Schild analysis was performed, and when the slope was not significantly different from unity, the pA₂ value was determined (pA₂—the negative log of molar concentration of the antagonist which reduces the effect of double dose of the agonist drug to that of a single dose). When the slope appeared to be significantly different from unity and the maximal response to 5-HT was not obtained, the pD₂' was calculated (pD₂'—negative logarithm of the molar concentration of antagonist, which reduces the effect of an agonist to 50% of its maximum).

**h5-HT<sub>3R</sub> Ion Channel Cell-Based Antagonist IonFlux Automated Patch Clamp Assay.** The functional properties of the selected compound FPPQ on 5-HT<sub>3R</sub> were evaluated using an electrophysiological assay in CHO-K1 cells using IonFlux HT platform.

All recordings were obtained from a holding potential of -60 mV. To establish the baseline response, serotonin was added at the concentration corresponding to its EC₈₀ value. Subsequently, the test
compound was characterized in a dose-response protocol at the concentration ranges from $10^{-6}$ to $10^{-11}$ M, with 30 s preincubation, followed by the addition of 5-HT at its EC$_{80}$ in the presence of the compound for 2 s.

Peak inward currents were measured in response to the serotonin additions in the presence of a single concentration of the compound. Obtained data have been normalized to the baseline peak current induced by the addition of EC$_{80}$ serotonin for 2 s, according to eq 1

$$ \text{normalized peak current} = \frac{I^{\text{compound+ser}}}{I^{\text{ser}}} \qquad (1) $$

Received data were analyzed using a four-parameter logistic equation in GraphPad Prism software. Experiment was performed Eurofins, France.

**Determination of 5-HT$_{6}$R Constitutive Activity at Gs Signaling.** cAMP measurement was performed in NG108-15 cells transiently expressing 5-HT$_{6}$R using the Bioluminescence Resonance Energy Transfer (BRET) sensor for cAMP, CAMYEL (cAMP sensor using YFP-Epac-RLuc).⁶⁵ NG108-15 cells were co-transfected in suspension with 5-HT$_{6}$R (or empty vector for Mock condition) and CAMYEL constructs, using Lipofectamine 2000, according to the manufacturer protocol, and plated in white 96-well plates (Greiner), at a density of 80 000 cells per well. Twenty-four hours after transfection, cells were washed with PBS containing calcium and magnesium. Coelenterazine H (Molecular Probes) was added at a final concentration of 5 µM, and left at room temperature for 5 min. BRET was measured using a Mithras LB 940 plate reader (Berthold Technologies).

**Impact of Compounds on Neurite Growth.** NG108-15 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% dialyzed fetal calf serum, 2% hypoxanthine/aminopterin/thymidine (Life Technologies), and antibiotics. Cells were transfected with plasmids encoding either cytosolic GFP or a GFP-tagged 5-HT$_{6}$R in suspension using Lipofectamine 2000 (Life Technologies) and plated on glass coverslips. Six hours after transfection, cells were treated with either DMSO (control), FPPQ, or intepirdine (1 µM) for 24 h. Cells were fixed in 4% paraformaldehyde (PFA) supplemented with 4% sucrose for 10 min. PFA fluorescence was quenched by incubating the cells in PBS containing 0.1 M glycine, prior to mounting in ProLong Gold antifade reagent (Thermo Fisher Scientific). Cells were imaged using an AxioImager Z1 microscope equipped with epifluorescence (Zeiss), using a 20× objective for cultured cells, and neurite length (index of 5-HT$_{6}$R constitutive activity as Cdk5 signaling) was assessed using the Neuron J plugin of the ImageJ software (NIH).

**Determination of Metabolic Stability in Rat and Human Liver Microsomes.** Test compounds were prepared in phosphate-buffered saline (PBS) from 10 mM dimethyl sulfoxide (DMSO) solution so that the final incubation concentration was 1 µM. Pooled human (Invitrogen) or rat (Pharmidex Pharmaceutical Services Ltd) liver microsomes were diluted in PBS to allow for a 0.5 mg/mL total protein concentration in the assay. Incubations were started by adding NADPH (Sigma-Aldrich) solutions and were performed at 37 °C for various periods of time (0, 5, 15, 30, 45, 60, and 120 min). The reaction was stopped with the precipitation buffer (cold acetonitrile with 0.1% formic acid containing internal standard tolbutamide (Sigma-Aldrich), 400 µg/mL); this was used to precipitate proteins and release compound. The samples were vortexed and incubated for 10 min on ice and then centrifuged for 10 min at 15 000g. The resulting supernatants were transferred to vials and stored at -70 °C. Supernatants were then analyzed by UHPLC-TOF MS. Assays were performed in triplicate in a total volume of 100 µL. Verapamil (Sigma-Aldrich) was used as a reference control.

**Analysis.** The samples were prepared for analysis by a fivefold dilution with 70/30 water/acetonitrile (25 µL of sample plus 100 µL of 70/30 water/acetonitrile). The samples were analyzed by high-resolution accurate mass UHPLC-TOF MS. The UPLC-MS system comprised an Agilent 1290 Infinity UHPLC pump with an Agilent 1290 Infinity HTS Autosampler, coupled with an Agilent 6550 iFunnel QTOF mass spectrometer, equipped with a Waters Acquy BEH Phenyl UPLC column (50 × 2.1 mm²), 1.7 µm particle size. The

system was controlled by MassHunter software vB.05.01. Gradient elution was employed with mobile phase components A and B being water/formic acid (0.1%, v/v) and acetonitrile/formic acid (0.1%, v/v), respectively. Initial conditions, from 0 to 0.3 min, were 2% B. Between 1.3 and 1.35 min %B was decreased to 2%, and this was maintained until the end of the run at 1.8 min. The flow rate was 0.4 mL/min, the injection volume was 5 µL, and the column was maintained at 50 °C. The mass spectrometer was operated in full scan mode, with positive ion electrospray data acquired over the m/z mass range 100-1000.

**Pharmacological and Safety Profile of FPPQ.** The binding and safety profile of FPPQ was investigated using the SafetyScreen TM Panel (Eurofins) including enzymatic (n = 13) and binding assays (n = 74), (https://www.eurofinsdiscoveryservices.com/catalogmanagement/viewitem/SafetyScreen87-Panel/Panlabs/PP223#assayInfo). Additionally, we included the binding assays for the following receptors: serotonin 5-HT$_{4}$ (ref 5), 272000-HT$_{5A}$ (ref 5), 272100-HT$_{7}$ (ref 272320), D$_{3}$ (ref 219800), histamine H$_{3}$ (ref 239820), sigma 1 (ref 278110), and enzymatic assays: CYP450, 1A2 (ref 2064), CYP450, 2C19 (ref 1772), CYP450, 2C9 (ref 2066), CYP450, 2D6 (ref 1838), CYP450, 3A4 (ref 1769) to evaluate possible metabolic interactions.

**Determination of Agonist Effect of FPPQ for 5-HT$_{2B}$ Receptors.** Agonistic effect of compound FPPQ was determined as inhibition of $10^{-6}$ M serotonin using the HTRF technique. Experiment was performed in duplicate at Eurofins, France.

**Determination of Mutagenic Potential of FPPQ.** Sodium azide (SA), 4-nitro-o-phenylenediamine (NPD, magnesium sulfate, sodium ammonium phosphate, D-glucose, D-biotin, sodium chloride, L-histidine HCl, L-tryptophane, dimethyl sulfoxide (DMSO), sodium phosphate-dibasic, citric acid monohydrate, potassium phosphate-dibasic, and sodium phosphate-monobasic were purchased from Sigma-Aldrich. Oxoid Nutrient Broth No. 2 (Oxoid Ltd.) and Agar-agar (Merck) were used as bacterial media.

**Salmonella Mutagenic Assay.** Mutagenic activity was tested by the Salmonella assay, using the *Salmonella Typhimurium* tester strains TA98, TA100, TA1535, and TA1537, kindly provided by Dr. T. Nohmi, Division of Genetics and Mutagenesis, National Institute of Hygienic Sciences, Tokyo, Japan, by the preincubation method. Selection of the strains was based on the testing and strain selection strategies of Mortelmans and Zeiger.⁶⁶ The strains from frozen cultures were grown overnight for 12-14 h in Oxoid Nutrient Broth No. 2. Five different doses of test compounds were assayed. All of them were diluted in DMSO. The concentrations were selected on the basis of a preliminary toxicity test. The various concentrations of tested compounds were added to 300 µL of 0.2 M phosphate buffer (pH 7.4) and 60 µL of bacterial culture and then incubated at 37 °C for 20-30 min. After this time, 1200 µL of top agar was added to the mixture and poured on to a plate containing minimal agar. The plates were incubated at 37 °C for 48 h and the revertant colonies were counted manually. All experiments were analyzed in triplicate. Mutagenic activity is expressed as number of His+ induced revertants (mean ± standard deviation) for all tested doses. The standard mutagens used as positive controls were 4-nitro-o-phenylenediamine (0.25 µg/plate) for TA98 and TA1537, sodium azide (0.5 µg/plate) for TA100 and TA1535. DMSO served as the negative (solvent) control.

**Pharmacokinetic (PK) Profile of FPPQ.** Lister Hooded (Envigo, U.K.) rats were administered with FPPQ (0.3, 1, and 3 mg/kg, p.o.) for assessment of serial plasma and terminal brain exposures for PK bio-analysis. Plasma levels were determined at 1, 2, 3, 4, 5, 8, 24, and 32 h after FPPQ administration (n = 3/time point). Blood samples were obtained by direct venipuncture from the tail and spun in a cooled centrifuge. Plasma aliquots (170 µL minimum) were stored frozen (-80 °C) until analysis. Brain levels were determined at 3, 4, 5, and 32 h after FPPQ administration. Brains were removed from the skull, briefly rinsed, hemisected, weighed, and stored frozen (-80 °C) until used. The samples were analyzed by UPLC-MS/MS (liquid chromatography-tandem mass spectrometry using electrospray ionization). The UPLC-MS/MS system comprised an Agilent 6410
triple quadrupole mass spectrometer coupled with an Agilent 1200 series UHPLC pump and autosampler. The system was controlled by MassHunter software vB.01.04. Sample analysis of FPPQ was carried out in positive ion electrospray mode for the following reaction monitoring transitions, precursor ion (m/z) = 411.1 and fragment ion (m/z) = 184.3. Chromatographic separations were achieved using a Kinetex C18 column (5 µm, 50 × 2.1 mm², Phenomenex, U.K.) maintained at 50°C. The mobile phase consisted of water + 0.1% formic acid (solvent A) and acetonitrile + 0.1% formic acid (solvent B) programmed to linearly increase the proportion of solvent B as detailed: time after injection – 0 min (5% B), 0.3 (5% B), 1.9 min (95% B), 2.3 (95% B), 2.4 (5% B), 3.4 (5% B).

On the day of analysis, plasma samples were thawed and vortex mixed. Control plasma was spiked with SP14040 to create calibration standards. Aliquots (50 µL) of the samples were transferred to separate wells in a 96-well microtiter plate, to each of which was added 150 µL of IS solution. Blanks with no internal standard were prepared by the addition of either 150 µL of acetonitrile to 50 µL of control plasma. All samples were mixed on a rotary plate shaker (900 rpm, 20 min) and centrifuged (3000 rpm, 15 min). After centrifugation, aliquots (50 µL) of supernatant were transferred to separate wells in a 96-well microtiter plate containing water (100 µL) and mixed on a rotary plate shaker (450 rpm, 5 min) prior to analysis. On the day of analysis, brain samples were thawed, weighed and water added (1 mL/g tissue). Beads (zirconium oxide) were then added to the samples (1 g beads/g tissue) which were homogenized for 10 min at medium speed. Aliquots (50 µL) of homogenate brain samples were processed as described before for plasma aliquots.

**In Vivo Pharmacology. Animals.** A total of 55, 45, 38, and 56 male Sprague-Dawley rats (Charles River, Germany) weighing 250–280 g on arrival were used in FPPQ, SB399885, SB399588+ondansetron, and CPPQ+ondansetron PCP hyperactivity studies, respectively. For the NOR test, 44 Sprague-Dawley rats were used. The animals were housed in a temperature-controlled (21 ± 1 °C) and humidity-controlled (40–50%) colony room under a 12/12 h light/dark cycle (lights on at 06:00 h). The rats were group-housed (5/cage) with free access to food and water. Rats were allowed to acclimatize for at least 7 days before the start of the experimental procedures. Behavioral testing was performed during the light phase of the light/dark cycle. The experiments were conducted in accordance with the European Guidelines for animal welfare (2010/63/EU) and were approved by the II Local Ethics Committee for Animal Experiments at the Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.

**Spontaneous and PCP-Induced Hyperactivity.** Both spontaneous and PCP-induced locomotor activity were measured automatically in Opto-Varimex-4 Auto-Tracks (Columbus Instruments, Ohio) located in sound-attenuated and ventilated boxes. The Auto-Track System sensed the motion with a grid of infrared photocells (16 beams per axis) surrounding the arena.

**Drugs.** Clozapine (Abcam Biochemicals, Cambridge, U.K.) was dissolved in 0.1 N HCl supplemented with distilled water to the appropriate volume (final pH = 5.0–6.0). PCP HCl (Sigma-Aldrich), ondansetron (Tocris, U.K.), SB399885 (Tocris, U.K.), FPPQ, and CPPQ ((S)-1-[(3-chlorophenyl)sulfonyl]-4-(pyrrolidine-3-yl-amino)-1H-pyrrolo[3,2-c]quinolone)²⁹,⁶⁷ were dissolved in distilled water. All compounds were administrated in a volume of 1 mL/kg.

**Drugs Administration.** Separate groups of animals were administered FPPQ (1 and 3 mg/kg), clozapine (1 and 3 mg/kg), or their vehicles PO, before being placed individually into the auto-tracks for 30 min of spontaneous locomotor activity measurement. In the other experiments, SB399885, ondansetron, CPPQ, or their combinations were administered IP 60 min before being placed in activity boxes. Following 30 min of spontaneous activity measurement, the animals were removed from the boxes, injected with phencyclidine hydrochloride (PCP) at a dose of 5 mg/kg (SC), and then PCP-induced locomotor activity was measured for 120 min.

**Data Analysis.** The activity data collected every 5 min are presented as a raw readout as well as an Area Under Curve (AUC) of the distance traveled, in centimeters.

The measurements (30 min) preceding PCP administration indicate drug-induced effects on spontaneous locomotor activity. The second period (measured in the same animals at 0-120 min following PCP administration) indicates drug-induced alteration of PCP-induced hyperactivity.

Mixed-design two-way ANOVA with treatment(s) as between-subject factor and time as repeated measures factor on raw distance data, and separate one-way or two-way ANOVAs (on AUC data) followed by Dunnett's multiple comparison, LSD or Tukey's post hoc tests as well as analyses of contrast coefficients (Statistica 12 for Windows, IBM SPSS ver 26 for Mac) were used to assess the effects of compounds on activity. If not indicated otherwise, experimental design and drug doses were selected based on previous reports.⁶⁰

**Novel Object Recognition Test.** Procedures were based on earlier studies by Popik et al.⁵,⁶⁸ Rats were tested in a dimly lit (25 Lux) "open field" apparatus made of a dull gray plastic (66 × 56 × 30 cm³). After each measurement, the floor was cleaned and dried. The procedure lasting for 2 days consisted of the habituation to the test arena (without any objects) for 5 min. The test session comprising two trials separated by an intertrial interval (ITI) of 1 h was carried out on the next day. During the first trial (familiarization, T1) two identical objects (A1 and A2) were presented in the opposite corners of the open field, approximately 10 cm from the walls. During the second trial (recognition, T2), one of the A objects were replaced by a novel one so that the animals were presented with the A=familiar and B=novel objects. Both trials lasted for 3 min and the animals were returned to their home cages after T1. As the objects, the glass beakers filled with the gravel and the plastic bottles filled with the sand were used. The heights of the objects were comparable (~12 cm) and the objects were heavy enough not to be displaced by the animals. The sequence of presentations and the location of the objects was randomly assigned to each rat. By definition, the animals explore the objects when looking, licking, sniffing, or touching the object while sniffing, but not leaning against, standing, or sitting on the object. Any rat exploring the two objects for less than 5 s within 3 min of T1 or T2 was eliminated from the study. Exploration time of the objects and the distance traveled were measured manually and using the Any-maze video tracking system, respectively. Based on exploration time (E) of two objects during T2, discrimination index (DI) was calculated according to the formula: $DI = (EB-EA)/(EA+AB)$.

**Experimental Design.** Phencyclidine (PCP), used to attenuate learning, was administered at the dose of 5 mg/kg (IP) 45 min before familiarization phase (T1). The compounds were administrated *p.o.*, 30 min before PCP (i.e., 1 h and 15 min before T1).

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00224.

Experimental conditions for UPLC-MS, HRMS, and NMR analyses; ¹H NMR spectra of intermediates; ¹H NMR spectra and characterization of selected Boc-protected derivatives of final compounds; UPLC-MS, ¹H NMR, and ¹³C NMR spectra of final compounds; synthesis and characterization of compound II; evaluation of binding mode of derivatives with different basic moieties against 5-HT₃ and 5-HT₆ receptors; off-target selectivity of FPPQ; and mutagenicity risk assessment for FPPQ (PDF)

5-HT₃R crystal structure (PDB ID: 6NP0) (PDB)

5-HT₆R homology model on the adrenergic β-2 template coordinate file (PDB)

SMILE strings of all shown molecules and corresponding biological activity (CSV)
## AUTHOR INFORMATION

### Corresponding Authors

Pawel Zajdel - Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; ● orcid.org/0000-0002-6192-8721; Email: pawel.zajdel@uj.edu.pl

Piotr Popik - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; ● orcid.org/0000-0003-0722-1263; Email: nfpopik@cyf-kr.edu.pl

### Authors

Katarzyna Grychowska - Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; ● orcid.org/0000-0002-2264-251X

Szczepan Mogilski - Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland

Rafał Kurczab - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; ● orcid.org/0000-0002-9555-3905

Grzegorz Satala - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; ● orcid.org/0000-0002-0756-7232

Ryszard Bugno - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; ● orcid.org/0000-0003-3741-674X

Tomasz Kos - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland

Joanna Gołębiowska - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland

Natalia Malikowska-Racia - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; ● orcid.org/0000-0003-1250-7768

Agnieszka Nikiforuk - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; ● orcid.org/0000-0002-2424-8348

Séverine Chaumont-Dubel - Institut de Génomique Fonctionelle, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France; ● orcid.org/0000-0001-6860-6891

Xavier Bantreil - IBMM, Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France; ● orcid.org/0000-0002-2676-6851

Maciej Pawłowski - Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland

Jean Martinez - IBMM, Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France; ● orcid.org/0000-0002-9267-4621

Gilles Subra - IBMM, Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France; ● orcid.org/0000-0003-4857-4049

Frédéric Lamaty - IBMM, Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France; ● orcid.org/0000-0003-2213-9276

Philippe Marin - Institut de Génomique Fonctionelle, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France; ● orcid.org/0000-0002-5977-7274

Andrzej J. Bojarski - Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; ● orcid.org/0000-0003-1417-6333

Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.jmedchem.1c00224

### Notes

The authors declare no competing financial interest.

Analysis conducted using www.swissadme.ch resulted in no detectable PAINS—patterns for pyrroloquinolines 5d, 5e, and all of their sulfonyl derivatives 6–28.

## ACKNOWLEDGMENTS

This study was financially supported by the Polish Ministry of Science and Higher Education (MNiSW), Grant No. N N405 671540; the project "Prokog", UDA-POIG.01.03.01-12-063/ 09-00, co-financed by the European Union from the European Fund of Regional Development (EFRD); the Priority Research Area qLife under the program "Excellence Initiative—Research University" at the Jagiellonian University in Krakow; and statutory funds from the Maj Institute of Pharmacology, Polish Academy of Sciences, University of Montpellier, CNRS, INSERM and Agence Nationale de la Recherche (no. ANR-17-CE16-0013-01 and ANR-17-CE16-0010-01).

## ABBREVIATIONS USED

AUC, area under curve; BRET, bioluminescence resonance energy transfer; CLint, intrinsic clearance; 5-CT, 5-carboxytryptamine; AcOH, acetic acid; ANOVA, analysis of variance; BTPP, (tert-Butylimino)tris(pyrrolidino)phosphorane; Cdk5, cyclin-dependent kinase 5; DI, discrimination index; GABA, γ aminobutyric acid; GPCR, G-protein-coupled receptor; hERG, human ether-a-go-go related gene; 5-HT, 5-hydroxytryptamine; LGIC, ligand-gated ion channel; L-R complex, ligand-receptor complex; MED, minimal effective dose; MeOH, methanol; mTOR, mechanistic target of rapamycin; MW, microwave; NOR, novel object recognition; PCP, phencyclidine; SEM, standard error of the mean; TEA, triethylamine; TR-FRET, time-resolved fluorescence resonance energy transfer

## REFERENCES

(1) Meltzer, H. Y. Clozapine: Balancing safety with superior antipsychotic efficacy. *Clin. Schizophr. Relat. Psychoses* **2012**, *6*, 134–144.

(2) Stephens, P. A Review of clozapine: an antipsychotic for treatment-resistant schizophrenia. *Compr. Psychiatry* **1990**, *31*, 315–326.

(3) Lally, J.; Gaughran, F.; Timms, P.; Curran, S. R. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. *Pharmgenomics Pers. Med.* **2016**, *9*, 117–129.

(4) Wang, R. Y.; Ashby, C. R. J.; Edwards, E.; Zhang, J. Y. The role of 5-HT₃-like receptors in the action of clozapine. *J. Clin. Psychiatry* **1994**, *55*, 23–26.

(5) Arnt, J.; Skarsfeldt, T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. *Neuro-psychopharmacology* **1998**, *18*, 63–101.

(6) Millan, M. J.; Di Cara, B.; Dekeyne, A.; Panayi, F.; De Groote, L.; Sicard, D.; Cistarelli, L.; Billiras, R.; Gobert, A. Selective blockade of dopamine D₃ versus D₂ receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. *J. Neurochem.* **2007**, *100*, 1047–1061.

(7) Barnes, N. M.; Ahern, G. P.; Bécamel, C.; Bockaert, J.; Camilleri, M.; Chaumont-Dubel, S.; Claeysen, S.; Cunningham, K. A.; Fone, K. C.; Gershon, M.; Di Giovanni, G.; Goodfellow, N. M.; Halberstadt, A. L.; Hartley, R. M.; Hassaine, G.; Herrick-Davis, K.; Hovius, R.; Lacivita, E.; Lambe, E. K.; Leopoldo, M.; Levy, F. O.; Lummis, S. C. R.; Marin, P.; Maroteaux, L.; McCreary, A. C.; Nelson, D. L.; Neumaier, J. F.; Newman-Tancredi, A.; Nury, H.; Roberts, A.; Roth, B. L.; Roumier, A.; Sanger, G. J.; Teitler, M.; Sharp, T.; Villalón, C. M.; Vogel, H.; Watts, S. W.; Hoyer, D. International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-
hydroxytryptamine; pharmacology and function. *Pharmacol. Rev.* **2021**, *73*, 310–520.

(8) Turner, T. J.; Mokler, D. J.; Luebke, J. I. Calcium influx through presynaptic 5-HT₃ receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studies. *Neuroscience* **2004**, *129*, 703–718.

(9) Funahashi, M.; Mitoh, Y.; Matsuo, R. Activation of presynaptic 5-HT₃ receptors facilitates glutamatergic synaptic inputs to area postrema neurons in rat brain slices. *Methods Find. Exp. Clin. Pharmacol.* **2004**, *26*, 615–622.

(10) Dremencov, E.; Weizmann, Y.; Kinor, N.; Gispan-Herman, I.; Yadid, G. Modulation of dopamine transmission by 5-HT₂C and 5-HT₃ receptors: a role in the antidepressant response. *Curr. Drug Targets* **2006**, *7*, 165–175.

(11) Ellenbroek, B. A.; Prinssen, E. P. M. Can 5-HT₃ antagonists contribute toward the treatment of schizophrenia? *Behav. Pharmacol.* **2015**, *26*, 33–44.

(12) Akhondzadeh, S.; Mohammadi, N.; Noroozian, M.; Karamghadiri, N.; Ghoreishi, A.; Jamshidi, A. H.; Forghani, S. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. *Schizophr. Res.* **2009**, *107*, 206–212.

(13) Garay, R. P.; Bourin, M.; de Paillette, E.; Samalin, L.; Hameg, A.; Llorca, P. M. Potential serotonergic agents for the treatment of schizophrenia. *Expert Opin. Investig. Drugs* **2016**, *25*, 159–170.

(14) Levkovitz, Y.; Arnest, G.; Mendlovic, S.; Treves, I.; Fennig, S. The effect of ondansetron on memory in schizophrenic patients. *Brain Res. Bull.* **2005**, *65*, 291–295.

(15) Khodaie-Ardakani, M. R.; Seddighi, S.; Modabbernia, A.; Rezaei, F.; Salehi, B.; Ashrafi, M.; Shams-Alizadeh, N.; Mohammad-Karimi, M.; Esfandiari, G.-R.; Hajiaghaee, R.; Akhondzadeh, S. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled Study. *J. Psychiatr. Res.* **2013**, *47*, 472–478.

(16) Yun, H.-M.; Kim, S.; Kim, H.-J.; Kostenis, E.; Kim, J. Il.; Seong, J. Y.; Baik, J.-H.; Rhim, H. The novel cellular mechanism of human 5-HT₆ receptor through an interaction with Fyn. *J. Biol. Chem.* **2007**, *282*, 5496–5505.

(17) Meffre, J.; Chaumont-Dubel, S.; Mannoury la Cour, C.; Loiseau, F.; Watson, D. J. G.; Dekeyne, A.; Séveno, M.; Rivet, J. M.; Gaven, F.; Déléris, P.; Hervé, D.; Fone, K. C. F.; Bockaert, J.; Millan, M. J.; Marin, P. 5-HT₆ Receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. *EMBO Mol. Med.* **2012**, *4*, 1043–1056.

(18) Duhr, F.; Déléris, P.; Raynaud, F.; Séveno, M.; Morisset-Lopez, S.; Mannoury la Cour, C.; Millan, M. J.; Bockaert, J.; Marin, P.; Chaumont-Dubel, S. Cdk5 Induces constitutive activation of 5-HT₆ receptors to promote neurite growth. *Nat. Chem. Biol.* **2014**, *10*, 590–597.

(19) Deraredj Nadim, W.; Chaumont-Dubel, S.; Madouri, F.; Cobret, L.; De Tauzia, M. L.; Zajdel, P.; Benedetti, H.; Marin, P.; Morisset-Lopez, S. Physical interaction between neurofibromin and serotonin 5-HT₆ receptor promotes receptor constitutive activity. *Proc. Natl. Acad. Sci. U.S.A.* **2016**, *113*, 12310–12315.

(20) Vanda, D.; Soural, M.; Canale, V.; Chaumont-Dubel, S.; Satala, G.; Kos, T.; Funk, P.; Fülöpová, V.; Lemrová, B.; Koczurkiewicz, P.; Pękala, E.; Bojarski, A. J.; Popik, P.; Marin, P.; Zajdel, P. Novel non-sulfonamide 5-HT₆ partial inverse agonist in a group of imidazo[4,5-b]pyridines with cognition enhancing properties. *Eur. J. Med. Chem.* **2018**, *144*, 716–729.

(21) Vanda, D.; Canale, V.; Chaumont-Dubel, S.; Kurczab, R.; Satala, G.; Koczurkiewicz-Adamczyk, P.; Krawczyk, M.; Pietruš, W.; Blicharz, K.; Pękala, E.; Bojarski, A. J.; Popik, P.; Marin, P.; Soural, M.; Zajdel, P. Imidazopyridine-based 5-HT₆ receptor neutral antagonists: impact of N1-benzyl and N1-phenylsulfonyl fragments on different receptor conformational states. *J. Med. Chem.* **2021**, *64*, 1180–1196.

(22) Tassone, A.; Madeo, G.; Schirinzi, T.; Vita, D.; Puglisi, F.; Ponterio, G.; Borsini, F.; Pisani, A.; Bonsi, P. Activation of 5-HT₆

receptors inhibits corticostriatal glutamatergic transmission. *Neuropharmacology* **2011**, *61*, 632–637.

(23) Codony, X.; Vela, J. M.; Ramírez, M. J. 5-HT₆ Receptor and cognition. *Curr. Opin. Pharmacol.* **2011**, *11*, 94–100.

(24) Ivachtchenko, A. V.; Lavrovsky, Y.; Ivanenkov, Y. A. AVN-211, Novel and highly selective 5-HT₆ receptor small molecule antagonist, for the treatment of Alzheimer's disease. *Mol. Pharm.* **2016**, *13*, 945–963.

(25) https://clinicaltrials.gov/ct2/show/NCT00810667 (accessed Jan 12, 2021).

(26) Bolognesi, M. L. Polypharmacology in a single drug: multitarget drugs. *Curr. Med. Chem.* **2013**, *20*, 1639–1645.

(27) Proschak, E.; Stark, H.; Merk, D. Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds. *J. Med. Chem.* **2019**, *62*, 420–444.

(28) Campiani, G.; Cappelli, A.; Nacci, V.; Anzini, M.; Vomero, S.; Hamon, M.; Cagnotto, A.; Fracasso, C.; Uboldi, C.; Caccia, S.; Consolo, S.; Mennini, T. Novel and highly potent 5-HT₃ receptor agonists based on a pyrroloquinoxaline structure. *J. Med. Chem.* **1997**, *40*, 3670–3678.

(29) Grychowska, K.; Satala, G.; Kos, T.; Partyka, A.; Colacino, E.; Chaumont-Dubel, S.; Bantreil, X.; Wesolowska, A.; Pawlowski, M.; Martinez, J.; Marin, P.; Subra, G.; Bojarski, A. J.; Lamaty, F.; Popik, P.; Zajdel, P. Novel 1H-pyrrolo[3,2-c]quinoline based 5-HT₆ receptor antagonists with potential application for the treatment of cognitive disorders associated with Alzheimer's disease. *ACS Chem. Neurosci.* **2016**, *7*, 972–983.

(30) Bolognesi, M. L. Harnessing polypharmacology with medicinal chemistry. *ACS Med. Chem. Lett.* **2019**, *10*, 273–275.

(31) Lecoutey, C.; Hedou, D.; Freret, T.; Giannoni, P.; Gaven, F.; Since, M.; Bouet, V.; Ballandonne, C.; Corvaisier, S.; Malzert Fréon, A.; Mignani, S.; Cresteil, T.; Boulouard, M.; Claeysen, S.; Rochais, C.; Dallemagne, P. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. *Proc. Natl. Acad. Sci. U.S.A.* **2014**, *111*, E3825–E3830.

(32) Canale, V.; Grychowska, K.; Kurczab, R.; Ryng, M.; Keeri, A. R.; Satala, G.; Olejarz-Maciej, A.; Koczurkiewicz, P.; Drop, M.; Blicharz, K.; Piska, K.; Pękala, E.; Janiszewska, P.; Krawczyk, M.; Walczak, M.; Chaumont-Dubel, S.; Bojarski, A. J.; Marin, P.; Popik, P.; Zajdel, P. A Dual-acting 5-HT₆ receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties. *Eur. J. Med. Chem.* **2020**, *208*, No. 112765.

(33) (a) Zajdel, P.; Grychowska, K.; Lamaty, F.; Colacino, E.; Bantreil, X.; Martinez, J.; Pawlowski, M.; Satala, G.; Bojarski, A. J.; Partyka, A.; Wesolowska, A.; Kos, T.; Popik, P.; Subra, G. Pyrroloquinoline Derivatives as 5-HT₆ Antagonists, Preparation Method and Use Thereof. WO2015012704A12015. (b) Celada, P.; Artigas, F.; Castane, A.; Riga, M.; Cano Biosca, M.; Ruiz-Avila, L.; Zajdel, P.; Lamaty, F.; Popik, P. Composition for the Treatment of Schizophrenia And/or Psychosis. WO2019180176A12019.

(34) Grychowska, K.; Chaumont-Dubel, S.; Kurczab, R.; Koczurkiewicz, P.; Deville, C.; Krawczyk, M.; Pietruš, W.; Satala, G.; Buda, S.; Piska, K.; Drop, M.; Bantreil, X.; Lamaty, F.; Pękala, E.; Bojarski, A. J.; Popik, P.; Marin, P.; Zajdel, P. Dual 5-HT₆ and D₃ receptor antagonists in a group of 1H-pyrrolo[3,2-c]quinolines with neuroprotective and procognitive activity. *ACS Chem. Neurosci.* **2019**, *10*, 3183–3196.

(35) Zajdel, P.; Marciniec, K.; Satala, G.; Canale, V.; Kos, T.; Partyka, A.; Jastrzębska-Więsek, M.; Wesolowska, A.; Basińska-Ziobroń, A.; Wójcikowski, J.; Daniel, W. A.; Bojarski, A. J.; Popik, P. N1-Azinylsulfonyl-1H-indoles: 5-HT₆ receptor antagonists with procognitive and antidepressant-like properties. *ACS Med. Chem. Lett.* **2016**, *7*, 618–622.

(36) Basak, S.; Gicheru, Y.; Kapoor, A.; Mayer, M. L.; Filizola, M.; Chakrapani, S. Molecular mechanism of setron-mediated inhibition of full-length 5-HT₃A receptor. *Nat. Commun.* **2019**, *10*, No. 3225.
(37) Johansson, G.; Engstromsgt, A. New Compounds Useful for the Treatment of Obesity, Type II Diabetes and CNS Disorders. WO2004/008282003.

(38) Cappelli, A.; Butini, S.; Brizzi, A.; Gemma, S.; Valenti, S.; Giuliani, G.; Anzini, M.; Mennuni, L.; Campiani, G.; Vomero, V. B.; et al. The interactions of the 5-HT₃ receptor with quipazine-like arylpiperazine ligands. The journey track at the end of the first decade of the third millennium. *Curr. Top. Med. Chem.* **2010**, *10*, S04-S26.

(39) Chaumont-Dubel, S.; Dupuy, V.; Bockaert, J.; Bécamel, C.; Marin, P. The 5-HT₆ receptor interactome: new insight in receptor signaling and its impact on brain physiology and pathologies. *Neuropharmacology* **2020**, *172*, No. 107839.

(40) Nadim, W. D.; Chaumont-Dubel, S.; Madouri, F.; Cobret, L.; De Tauzia, M.-L.; Zajdel, P.; Bénédetti, H.; Marin, P.; Morisset-Lopez, S. Physical interaction between neurofibromin and serotonin 5-HT₆ receptor promotes receptor constitutive activity. *Proc. Natl. Acad. Sci. U.S.A.* **2016**, *113*, 12310-12315.

(41) Engmann, O.; Hortobágyi, T.; Pidsley, R.; Troakes, C.; Bernstein, H. G.; Kreutz, M. R.; Mill, J.; Nikolic, M.; Giese, K. P. Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition. *Brain* **2011**, *134*, 2408-2421.

(42) *Instant J Chem.*n 19.19.0.; program versio2019.

(43) http://www.swissadme.ch/index.php (accessed Jan 15, 2021).

(44) Meltzer, H. Y.; Horiguchi, M.; Massey, B. W. The Role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. *Psychopharmacology* **2011**, *213*, 289-305.

(45) Meltzer, H. Y.; Matsubara, S.; Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D₁, D₂ and serotonin 2 pKᵣ values. *J. Pharmacol. Exp. Ther.* **1989**, *251*, 238-246.

(46) Gravius, A.; Laszy, J.; Pietraszek, M.; Sághy, K.; Nagel, J.; Chambon, C.; Wegener, N.; Valastro, B.; Danysz, W.; Gyertyán, I. Effects of 5-HT₆ antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. *Behav. Pharmacol.* **2011**, *22*, 122-135.

(47) Wesołowska, A.; Nikiforuk, A. Effects of the brain-penetrant and selective 5-HT₆ receptor antagonist SB-399885 in animal models of anxiety and depression. *Neuropharmacology* **2007**, *52*, 1274-1283.

(48) Fijal, K.; Popik, P.; Nikiforuk, A. Co-administration of 5-HT₆ receptor antagonists with clozapine, risperidone, and a 5-HT₂A receptor antagonist: effects on prepulse inhibition in rats. *Psychopharmacology* **2014**, *231*, 269-281.

(49) Pehrson, A. L.; Pedersen, C. S.; Tølbøl, K. S.; Sanchez, C. Vortioxetine treatment reverses subchronic PCP treatment-induced cognitive impairments: a potential role for serotonin receptor-mediated regulation of GABA neurotransmission. *Front. Pharmacol.* **2018**, *9*, 1-17.

(50) du Jardin, K. G.; Jensen, J. B.; Sanchez, C.; Pehrson, A. L. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT₁A receptor agonism and 5-HT₃ receptor antagonism. *Eur. Neuropsychopharmacol.* **2014**, *24*, 160-171.

(51) Cardinal, R. N.; Aitken, M. R. F. ANOVA for the Behavioral Sciences Researcher; Lawrence Erlbaum Associates: London, 2006.

(52) Ennaceur, A.; Delacour, J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. *Behav. Brain Res.* **1988**, *31*, 47-59.

(53) Popik, P.; Holuj, M.; Nikiforuk, A.; Kos, T.; Trullas, R.; Skolnick, P. 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats. *Psychopharmacology* **2015**, *232*, 1025-1038.

(54) Hirst, W. D.; Stean, T. O.; Rogers, D. C.; Sunter, D.; Pugh, P.; Moss, S. F.; Bromidge, S. M.; Riley, G.; Smith, D. R.; Bartlett, S.; Heidbreder, C. A.; Atkins, A. R.; Lacroix, L. P.; Dawson, L. A.; Foley, A. G.; Regan, C. M.; Upton, N. SB-399885 is a potent, selective 5-HT₆ receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. *Eur. J. Pharmacol.* **2006**, *553*, 109-119.

(55) Riga, M. S.; Sánchez, C.; Celada, P.; Artigas, F. Involvement of 5-HT₃ receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. *Neuropharmacology* **2016**, *108*, 73-81.

(56) Riga, M. S.; Teruel-Martí, V.; Sánchez, C.; Celada, P.; Artigas, F. Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex. *Neuropharmacology* **2017**, *113*, 148-155.

(57) Kulkarni, J.; Thomas, N.; Hudaib, A.-R.; Gavrilidis, E.; Gurvich, C. Ondansetron – a promising adjunctive treatment for persistent schizophrenia. *J. Psychopharmacol.* **2018**, *32*, 1204-1211.

(58) Vanda, D.; Soural, M.; Canale, V.; Chaumont-Dubel, S.; Satala, G.; Kos, T.; Funk, P.; Fülöpová, V.; Lemrová, B.; Koczurkiewicz, P.; Pękala, E.; Bojarski, A. J.; Popik, P.; Marin, P.; Zajdel, P. Novel non-sulfonamide 5-HT₆ receptor partial inverse agonist in a group of imidazo[4,5-b]pyridines with cognition enhancing properties. *Eur. J. Med. Chem.* **2018**, *144*, 716-729.

(59) Łażewska, D.; Kurczab, R.; Więcek, M.; Kamińska, K.; Satala, G.; Jastrzębska-Więsek, M.; Partyka, A.; Bojarski, A. J.; Wesołowska, A.; Kiec-Kononowicz, K.; Handzlik, J. The computer-aided discovery of novel family of the 5-HT₆ serotonin receptor ligands among derivatives of 4-benzyl-1,3,5-triazine. *Eur. J. Med. Chem.* **2017**, *135*, 117-124.

(60) Zajdel, P.; Kos, T.; Marciniec, K.; Satala, G.; Canale, V.; Kamiński, K.; Holuj, M.; Lenda, T.; Koralewski, R.; Bednarski, M.; Nowiński, L.; Wójcikowski, J.; Daniel, W. A.; Nikiforuk, A.; Alepa, I.; Chmielarz, P.; Kuśmierczyk, J.; Bojarski, A. J.; Popik, P. Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. *Eur. J. Med. Chem.* **2018**, *145*, 790-804.

(61) Kurczab, R.; Canale, V.; Satala, G.; Zajdel, P.; Bojarski, A. J. Amino acid hot spots of halogen bonding: a combined theoretical and experimental case study of the 5-HT₇ receptor. *J. Med. Chem.* **2018**, *61*, 8717-8733.

(62) Partyka, A.; Kurczab, R.; Canale, V.; Satala, G.; Marciniec, K.; Pasierb, A.; Jastrzębska-Więsek, M.; Pawlowski, M.; Wesołowska, A.; Bojarski, A. J.; Zajdel, P. The impact of the halogen bonding on D₂ and 5-HT₁A/5-HT₇ receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties. *Bioorganic. Med. Chem.* **2017**, *25*, 3636-3648.

(63) Yung-Chi, C.; Prusoff, W. H. Relationship between the inhibition constant (Kᵢ) and the concentration of inhibitor which causes 50% inhibition (I₅₀) of an enzymatic reaction. *Biochem. Pharmacol.* **1973**, *22*, 3099-3108.

(64) van Rossum, J.; van den Brink, F. Cumulative dose-response curves. I. Introduction to the technique. *Arch. Int. Pharmacodyn. Ther.* **1963**, *143*, 240-246.

(65) Jiang, L. I.; Collins, J.; Davis, R.; Lin, K.-M.; DeCamp, D.; Roach, T.; Hsueh, R.; Rebres, R. A.; Ross, E. M.; Taussig, R.; Fraser, I.; Sternweis, P. C. Use of a CAMP BRET sensor to characterize a novel regulation of CAMP by the sphingosine 1-phosphate/G13 pathway. *J. Biol. Chem.* **2007**, *282*, 10576-10584.

(66) Mortelmans, K.; Zeiger, E. The Ames Salmonella/microsome mutagenicity assay. *Mutat. Res. Mol. Mech. Mutagen.* **2000**, *455*, 29-60.

(67) Berthoux, C.; Hamieh, A. M.; Rogliardo, A.; Doucet, E. L.; Coudert, C.; Ango, F.; Grychowska, K.; Chaumont-Dubel, S.; Zajdel, P.; Maldonado, R.; Bockaert, J.; Marin, P.; Bécamel, C. Early 5-HT₆ receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. *EMBO Mol. Med.* **2020**, *12*, No. e10605.

(68) Popik, P.; Holuj, M.; Nikiforuk, A.; Kos, T.; Trullas, R.; Skolnick, P. 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats. *Psychopharmacology* **2015**, *232*, 1025-1038.